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ABSTRACT 
 
 The utilization of natural products as therapeutic agents has been an invaluable 
resource throughout medicinal history. Through the combined application of 
combinatorial biosynthesis, the modification of a natural product by engineered 
enzymes, and the isolation of new bioactive natural products, the discovery of new 
therapeutic agents may be achieved. This work shows the novel enzymatic interaction in 
the biosynthesis of a known therapeutic agent and the isolation of a new bioactive 
natural product. 
 Azinomycin A and B are antitumor natural products, isolated from Streptomyces 
sahachiroi. It was proposed that the biosynthesis of azinomycins is achieved through 
polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) machinery. In 
order to characterize the role of the PKS (AziB), enzymatic assays were analyzed by 
HPLC, LC-MS, and spectrophotometric methods. Although AziB was predicted to 
catalyze the production of 5-methyl-1-napthoic acid, a building block of azinomycins, a 
thioesterase (AziG) was found to be essential. Kinetic and crystallographic studies 
suggested the importance of the interaction of AziB and AziG to facilitate optimal 
enzymatic activity. The derivative of the AziB-AziG product is hypothesized to be 
assembled into the azinomycin backbone by NRPSs. In order to confirm the significance 
of a NRPS (AziA2) in the azinomycin biosynthetic pathway, gene knockout studies were 
performed. Fermentation of ∆aziA2 S. sahachiroi led to an cryptic overproduction of 
dimethyl furan-2,4-dicarboxylate. This showed an example of bacterial adaptation where 
bacteria start overproducing a new secondary metabolite to deal with the absence of a 
bioactive natural product. 
 A novel bioactive 40-membered macrolactone, Nuiapolide, was identified from a 
cyanobacterium collected from the Hawaiian ocean. This molecule has a rare tert-butyl 
side chain and nine hydroxyl groups distributed through the large hydrocarbon ring 
structure. Nuiapolide could inhibit metastatic activity of Jurkat at the concentration of as 
low as 1.3 µM without killing the cells. 
 iii 
 
 In this dissertation, the new functionality of a class of enzyme, the effect of 
biosynthetic disruption, and a novel anti-metastatic natural product from a marine source 
will be discussed. This information leads to a new understanding of natural products and 
their biosynthesis, which will eventually help researchers developing novel therapeutic 
agents. 
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CHAPTER I 
 
INTRODUCTION: NATURAL PRODUCTS AND THEIR BIOSYNTHESIS 
 
INTRODUCTION 
 
 Natural products are secondary metabolites which living organisms synthesize to 
survive the stress of various environmental conditions including changes in the weather 
and the existence of competitors or invaders. Many of these molecules are used as 
weapons to attack competitors. Plants produce antibiotics or antifungals to defend 
against invading pathogens, and microorganisms produce toxic materials to kill other 
microbes living in the same habitat.
9, 10
 These natural products can often be used as 
therapeutic agents for higher-order organisms when they are properly applied because 
many of these anti-infectious molecules are effective against a broad spectrum of 
microorganisms.
11
 The first antibiotic used as a therapeutic agent, penicillin (Figure 1), 
was isolated from the mold Penicillium glaucum. It was initially observed as having 
antibiotic activity against Staphylococcus spp.,
12
 but its derivatives have been shown to 
be effective against many other bacterial infections including Gram-positive bacteria, 
such as Streptococci, Clostridium, and Listeria genera.
13
 Since then natural product 
exploration has been one of the primary interests in drug discovery because the large 
degree of structural diversity can deliver highly potent lead compounds. 
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Figure 1. Structures of penicillin derivatives 
 
 
 
HISTORICAL PERSPECTIVE 
 
Primitive Use of Natural Products 
 Plants have been used by humans as herbal drugs for a long time. Archaeological 
evidence suggests that medicinal plants were used by Neanderthals during the Paleolithic 
period, approximately 60,000 years ago.
14
 A large amount of pollen from eight flowering 
plants, seven of which are currently used as herbal remedies, was found at Shanidar cave 
located in northern Iraq. More recent work has shown that dental plaques isolated from 
50,000 year old Neanderthals at El Sidrón site in northern Spain contained trace amounts 
of the known herbal plant Achillea millefolium.
15
 The plant was unlikely suitable for 
regular consumption because of its extremely bitter taste which is sensed by a taste 
receptor shared with Neanderthals and modern humans.
16
  
The oldest written history describing the medicinal uses of herbs dates back to 
3,000 B.C. when Sumerians in Mesopotamia documented the practice of preparing clay 
tablets with hundreds of medicinal plants including myrrh and opium.
17
 Ancient 
Egyptians wrote Ebers Papyrus in approximately 1500 B.C. containing information of 
more than 850 herbal medicines made from garlic, juniper, cannabis, castor bean, aloe, 
and mandrake.
18
 This list included many plants of foreign origin, suggesting that they 
had been trading for these medicinal plants with other nations. Through development of 
 3 
 
Ayurveda (science of long life) in India, spices which could be either food components 
or medicines were developed more than 5,000 years ago. For example, turmeric was 
derived from the rhizome of the plant Curcuma longa which contains a variety of 
bioactive natural products.
19
 The history of China has been written since 722 B.C. during 
the Zhou dynasty when Chinese medicine had already been established as an 
independent field of study with a variety of practitioners, such as physicians, surgeons, 
dietitians, and veterinarians. Archeological evidence from the Shang dynasty (16-11
th
 
century B.C.) has demonstrated their utilization of herbal medicines at that time.
20
 
Plants for medical purposes are consumed not only by humans but also by 
animals, and it is often observed in both mammals and birds. These behaviors are 
discussed in zoopharmacognosy.
21
 A well known example of animal self-medication is 
that chimpanzees consume the plant Aspilia spp. for the treatment or prevention of 
intestinal nematode parasites.
22, 23
 The plant contains a bioactive natural product, 
thiarubrine A, which is toxic to several parasitic nematode species.
21, 24
 Chimpanzees 
have a unique practice of using the plant. They eat only young leaves with 2-10 cm long 
and up to 4 cm broad by rolling it around in their mouth and swallow a whole without 
chewing so that a sufficient amount of bioactive molecules is protected by leaf structure 
and kept from digestion by stomach acid.
21
 Another well known example is anting, 
observed in more than 200 species of song birds, when birds wipe ants or other insects 
vigorously through their plumage.
25
 It is theorized that the behavior is to protect 
themselves with chemical fluids secreted by insects, such as formic acid, which act as 
anti-infectious agents.
26
 
 
Development of Natural Product Pharmacology 
  The Significance of natural products had been naturally and empirically shown, 
but the common viewpoint changed dramatically with the advancement of chemistry in 
the early nineteenth century. During this time, practitioners and physicians began to 
identify chemical compounds in medical plants which led to vigilant research on the 
therapeutic potential of plant components.
27
 Apothecaries and then pharmaceutical 
 4 
 
companies developed relatively crude therapeutic formulations from plant extracts, 
which had become purer and purer through the development of chemical analysis 
techniques until the mid-twentieth century when single molecule drugs derived from 
natural products started emerging.
28
  
The use of natural products entered into a new era with the discovery of 
penicillin, the first pure antibiotic drug, by Alexander Fleming in 1928. He showed that 
Penicilium rubens cultured in appropriate condition secreted an antibiotic substance 
which inhibited growth of other bacteria.
12, 29
 Penicillin was not introduced to the public 
market until the mid-1940s due to the lack of mass production techniques, although the 
therapeutic potential had already been displayed by Howard Florey and his colleagues. 
They showed that the antibiotic had a high toxicity against certain bacteria with a low 
toxicity to humans.
30, 31
 In a few years after their studies were published, thousands of 
cases were treated with penicillin and reported in hundreds of papers in the scientific 
community after production difficulties were overcome during World War II.
32
 Success 
of penicillin led researcher to investigate microbes as sources of potential therapeutic 
agents. Technological advancement has broadened explorable sites on earth over time 
allowing researchers to obtain novel sources of natural products. 
 
Current Status 
Natural product research began declining in the late 1980s due to the increasing 
development of synthetic drugs thanks to the technological development of organic 
synthesis.
33
 Synthetic drugs had a high impact on the pharmacological society because 
these molecules can be produced at a much larger scale with a much smaller facility. As 
comparing a small round bottomed flask producing grams of product in synthetic 
methods to a large fermenter producing milligrams of product in biological methods, the 
synthetic method provides robust drugs at a cheap price, which is crucial for poor 
people, especially in developing countries. Structures of synthetic drugs are typically 
simpler than ones of natural products, which make the synthetic compounds easy to be 
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mass produced and to be handled, but the simpler structures tend to lack the specificity 
and selectivity to drug targets leading to greater adverse effects to patients.  
The continuous exploration of natural products has supplied a great diversity of 
bioactive compounds which cannot be replaced by synthetic drugs. Natural products 
have demonstrated their importance in drug discovery, especially after the substantial 
innovation of high throughput screening (HTS) in the early 1990s. HTS uses automated 
robots and powerful computers to screen and analyze a large number of molecules at a 
time. The number of assays per day had reached 200,000 by the middle 2000s; although 
lack of facilities, which required expensive equipment that was only accessible by big 
pharmaceutical companies, still limited access to the procedure.
33
 One of the recent 
advancements in the HTS method was grown out of conventional plate assays. The well 
plates were replaced by pico-litter scale aqueous drops spread on oil surface as the 
reaction vessel. Thousands of these could be screened in a second, allowing ~1×108 
enzymatic reactions with a total of <150 µL reagent to be performed in 10 h.34 These 
technological advances made research much quicker, providing an enormous library of 
bioactive compounds to be studied. These compounds provided leads which researchers 
could use for designing novel therapeutic agents. 
Natural product exploration has been a leading theme in drug discovery for more 
than 50 years and never lost attention, although interest rose and fell occasionally due to 
changing trends. For 30 years, from 1981 to 2010, 33.8% of approved small molecule 
drugs were natural products, natural product botanical (botanical defined mixture), or 
natural product derived, and 16.5% of them were synthetic compounds with the same 
pharmacophore as natural products (Figure 2).
1
 The high ratio of natural product related 
drugs, and their steady contribution to drugs available, shows the significance of natural 
product research. This reasearch will likely receive more attention in the future because 
new sources of natural products have been recognized recently. Natural product 
botanical extracts (NB) are a mixture of multiple weak bioactive materials or of 
previously known drugs that have been shown to significantly elevate the therapeutic 
effect of a treatment when compared to an equal amount of the active single drug. The 
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plant extracts have been recognized again as novel drug formulations, although the 
individual molecules had been extensively focused since the discovery and success of 
penicillin.
35, 36
  
Sources of natural products which people can access and investigate has 
significantly extended thanks to technological, engineering, and scientific development. 
Marine natural products produced by invertebrates or microorganisms were made 
possible to investigate by the advancement of scuba technologies in the late twentieth 
century. This has lead to a growing number of marine natural products in preclinical 
studies and following clinical trials, and a few that have passed clinical trials in recent 
years. The quantity of clinically applicable marine natural products is thought to increase 
in the near future. In Europe no antitumor drug of marine origin had been approved since 
cytarabine come onto the market in 1969 until trabectedin (Yondelis®), isolated from 
the seasquirt Ecteinascidia turbinate, was approved for treatment of advanced or 
metastatic soft tissue sarcoma in 2007.
37
 Other sources of natural product drugs include 
venom or secretion of higher-order organisms, such as insects, reptiles, and amphibians, 
which often formulate a cocktail of bioactive peptides and/or small molecules to catch 
pray or to protect themselves from enemies or infection.
38
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Figure 2. Drug trend from 1981 to 2010 
1
 
N: natural product, NB: natural product botanical, ND: natural product derived, S: 
synthetic, S/NM: synthetic of a competitive inhibitor of an enzyme or receptor (natural 
product mimic), S*: synthetic with a natural product pharmacophore, S*/NM: synthetic 
with a natural product pharmacophore of a competitive inhibitor. Total number is 1073. 
The top graph displys the ratio of the souce of approved small molecule drugs in the 
period, and the bottom one shows the percentage of natural product in approved small 
molecule drugs in each year. 
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NATURAL PRODUCTS IN CANCER THERAPY 
 
 Cancer is one of the primary causes of death in developed countries, which tend 
to have higher average life expectancy, because the number of cases increases as the 
population ages. In The United States of America cancer was the second highest cause of 
death, preceded by heart (cardiovascular) diseases in 2010.
39
 In The European Union 
(EU), Australia, Canada, and Japan, cancer was the leading cause of death in 2010 (EU 
and Australia), in 2011 (Canada), and in 2012 (Japan).
40-43
 Cancer is traditionally treated 
by surgery, radiotherapy, chemotherapy, or their combination. In surgery and 
radiotherapy, cancer cells are physically removed from the affected sites or destroyed 
with high energy radiation. Drugs are used in chemotherapy for killing the cancerous 
cells or limiting cell behaviors, such as growth and spreading. Because sensitivity to 
these treatment strategies is varied in each cancer type and in each patient, other options 
are not likely to disappear even if one of them becomes predominantly effective and 
common. Most patients diagnosed with cancers have received chemotherapy in some 
form. Cancer is caused by failure of apoptosis after bodily cells undergo certain 
mutations, which occur due to either internal or external factors. Internal factors include 
inherited traits passed down by parents, and genetic mutations caused by aging. The 
primary example of an external source is exposure to carcinogens. There are countless 
numbers of cancer types because all body cells have the possibility to become cancerous. 
Some cancers are much more common than others, such as lung cancer, prostate cancer 
for men, and breast cancer for women. Therefore, an active drug to a particular cancer 
may not necessarily be active against other cancers, which make cancer therapies highly 
complicated.  
The enormous structural diversity of natural products, which can often 
selectively affect certain types of cancer cells, provides a solution to this problem. 
Bioactive natural products against cancer cells have been found from various sources, 
such as plants, terrestrial microorganisms, and marine microbes or invertebrates. Several 
successful antitumor natural products or natural product derivatives include paclitaxel, 
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vinorelbine, and vindesine from plants, bleomycins, anthracyclines, and epothilones 
from terrestrial microbes, and didemnin B, trabectedin, and halichondrin B from marine 
organisms (Figure 4).
44-46
 From 1930 to 2012, natural products, natural product 
botanical, or natural product derived small molecules accounted for 46.6% of all 
approved small molecules for cancer therapy, and synthetic compounds sharing a 
pharmacophore with natural products accounted for 20.4 % of all (Figure 3).
2
 This 
clearly shows the importance of natural products and their structural properties. 
 
 
 
Figure 3. Small molecule drugs for cancer therapy from 1930 to 2012 
2
  
Abbreviations are identified in Figure 2. Total number is 191. 
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Figure 4. Anticancer drugs 
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 One of the most notable antitumor drugs of natural source is paclitaxel (taxol®), 
which is used for the treatment of breast, ovarian, lung, bladder, prostate, melanoma, 
esophageal, Kaposi’s sarcoma, and some other solid tumors. Paclitaxel was discovered 
in 1962 by the National Cancer Institute (NCI) granted large scale screening program for 
antitumor agents from 1960s to early 1980s when 15,000 plant samples worldwide were 
evaluated against the mouse leukemia cell line.
47
 It was originally isolated from bark of 
the Pacific yew Taxus brevifolia and later found that it was produced by the fungus 
Taxomyces andreanae infecting the plant surface.
48
 Although it spent more than 10 years 
to be confirmed as an antitumor agent, 20 years to begin phase I clinical trials, and 30 
years to be approved by FDA, the plant alkaloid is now one of the most successful 
antitumor drugs on the market. It was the first one to reach sales greater than $1 billion, 
and peaked at $1.6 billion in late 2000 when the generic form was available on the 
market.
49
 Natural sources of bioactive compounds are not always sufficient for 
investigations, clinical trials, and practical uses. For example, T. brevifolia had already 
been scarce at the time of paclitaxel discovery, and it could not meet increasing demand 
of the compound. This issue was later solved by the establishment of the practical semi-
synthetic route from its analogous compound isolated from T. baccata.
50, 51
 
This kind of problem can also be tackled by total synthesis which allows for the 
generation of an enormous library of small molecule analogs. These can be screened to 
identify the pharmacophore of the parental compound, allowing for the development of 
safer or more powerful drugs. Pixantrone (pixuvri®) and mitoxantrone (novantrone®) 
are examples of synthetic drugs possessing a shared pharmacophore with natural 
products, the anthracyclines produced by Streptomyces spp. Anthracyclines are a class of 
drugs among the most effective anticancer treatments, but they have an irreversible 
cardiotoxic adverse reaction. This was settled by synthetic studies uncovering 
compounds with low toxicity that retained their antitumor activity. (Figure 5).
52
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Figure 5. Anthracycline analogs 
Daunorubicin and doxorubicin are natural origin prototypes of anthracycline drugs. 
Mitoxantrone is a synthetic drug derived from anthracyclines. Pixantrone is an 
experimental drug which is less toxic than mitoxantrone. 
 
 
 
BIOSYNTHESIS OF NATURAL PRODUCTS 
 
Importance of Enzymology 
 Natural products are synthesized by the combination of diverse enzymes. 
Enzyme structures have been optimized through the process of evolution since the 
appearance of the first organism, or even before that, for specific functions which are 
essential or desired for survival and reproduction. This has created a magnificent variety 
of enzymes. The structue of an enzyme is coded by a gene whose sequence is easily 
alterred, but these mutations do not necessariliy lead to bad outcomes. The mutated 
enzyme sometimes produces a new metabolite which increases the organisms’s 
survivability in its environment, and may become the new standard for the organism in 
the later generations.  
In other words, modifications to the biosynthetic pathway of a particular natural 
product may lead to novel bioactive compounds which are difficult to obtain through 
total or semi synthetic methods.
53, 54
 The expanded diversity of small molecules by 
combinatorial biosynthesis, generating non-natural natural products by engineered 
proteins, may relieve some of the difficulties on time and cost in drug discovery. 
Releasing a new drug currently takes approximately 13.5 years and costs about $1.8 
billion.
55
 The large modular proteins polyketide synthases (PKSs) and non-ribosomal 
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peptide synthetases (NRPSs) are well suited for the purpose of modifications on natural 
product structures by swapping or deleting the catalytic domains.
56
  
 
Polyketide Synthase (PKS) 
 PKS is one of the largest class of enzyme families synthesizing an enormous 
variety of natural products including long chained, cyclic, and aromatic compounds 
(Figure 6).
57-63
 The highly diversed structures are constructed by the complex 
combination of enzyme modules which consist of multiple functional domains. The 
fundamental domains which essentially all PKS proteins possess include acyl-transferase 
(AT), keto-synthase (KS), and acyl carrier protein (ACP) domains.
64
 These domains 
catalyze polyketide chain elongation with coenzyme A (CoA) derived monomer units of 
one starter unit (typically acetyl-CoA) and multiple malonyl-CoA or methaylmalonyl-
CoA for building blocks. An AT domain transfers a (methyl)malonyl group onto an ACP 
domain, which posttranslationally obtains a flexible pantetheinyl arm from CoA on its 
active site serine residue. This process is catalyzed by a phosphopantetheinyl transferase 
(PPTase).
65
 The (methyl)malonyl group is subsequently condensed with either the starter 
unit or the elongating chain. The elongating chain is transferred from a previous ACP 
domain to the active site cysteine residue of a KS domain, which gives an additional unit 
onto the polyketide intermediate. Side chains of elongating polyketides can be modified 
by multiple sub domains. For instance, the ketone would be reduced to alcohol by keto 
reductase (KR) domain, which can be further reduced to alkene by dehydratase (DH) 
domain, which could be reduced more to alkane by enoyl reductase (ER) domain. The 
final product is generated by cycles of these amalogamated enzymatic functions and 
released from the final ACP domain by hydrolysis or intramolecular cyclization 
catalyzed by thioesterase (TE) domain (Scheme 1 and Scheme 3). 
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Figure 6. Polyketide (PK), nonribosomal peptide (NRP), or hybrid Natural 
Products 
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Scheme 1. General scheme of PKS 
AT: acyltransferase, KS: keto-synthase, ACP: acyl carrier protein, KR: ketoreductase, 
DH: dehydrogenase, ER: enoylreductase, TE: thioesterase. 
 
 
 
PKS is classified into three types.
64
 Type I PKS is large modular protein in which 
each domain is interacted in cis. Type I PKS is further divided into two sub groups, 
iterative PKS (IPKS) and modular PKS. In IPKS, the cycle of catalytic actions is 
repeated until the polyketide chain reaches a specific length, which enables one module 
alone to synthesize the final product from scratch. Therefore, products of IPKSs 
regularly posess repeated units with the same structural properties. Fatty acid derivatives 
are synthesized by fully reductive IPKSs. In contrast to IPKS, modular PKS synthesizes 
the product with multiple modules, each of which consists of domains responsible for 
constructing individual building block of the final product. Products of modular PKSs 
have diversed structural features in each unit resulting highly complex natural products. 
In type II PKS, also known as aromatic polyketide producers, individual catalytic 
domains are not physically connected but interacted with in trans.
66
 Its minimal set of 
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enzyme contains ACP, KSα, and KSβ (or CLF: chain length factor) which has high 
sequence similarity to KSα but lacks the key cysteine residue.
67
 Type II PKSs synthesize 
aromatic natural products by elongating polyketide chain iteratively in the active site 
between KSα and KSβ, which is thought to be a factor determining the chain length, 
followed by cyclization and aromatization. Type III PKS is identified as a PKS lacking 
its ACP domain. It directly uses malonyl-CoA as a substrate instead of tansferring it onto 
the posttranslationally modified long flexible phosphopantetheinyl arm on ACP 
domain.
68
 
 
Nonribosomal Peptide Synthetase (NRPS) 
NRPS is another class of enzyme family that produces an immense variety of 
natural products (Figure 6).
62, 63, 69, 70
 NRPSs are modular proteins consisting of multiple 
catalytic domains in a similar style as PKSs, but NRPSs produce peptide natural product 
instad of polyketides. The catalytic domains in NRPS include adenylation (A), 
condensation (C), and peptidyl carrier protein (PCP) domains, each of which 
corresponds to AT, KS, and ACP domains, respectively.
64
 The A domain activates a 
peptide building block with adenosine triphosphate (ATP) to transfer it onto a 
posttranslationally modified PCP domain. An amide bond formation between two 
substrates is catalyzed by a C domain, and the product is eventually released by a TE 
domain (Scheme 2). NRPS generally has a wider variety of subdomains for structural 
modification on the side chain which allows for nonribosomal peptides to increase the 
complexity, such as cyclization (Cy), epimerization (E), methyltransferaes (MT), 
reductase (Re), oxidase (Ox) and halogenation (Hal) domains.
64
 Contrary to the numbers 
of subdomains NRPSs have only one type, the large non-iterative modular protein 
likewise modular type I PKS.  
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Scheme 2. General scheme of NRPS 
A: adenylation, C: condensation, PCP: peptidyl carrier protein, TE: thioesterase. 
 
 
 
Thioesterase (TE) 
 PKSs, NRPSs, and fatty acid synthases (FASs) typically have a thioesterase (TE) 
domain at the final stage of the sequential reaction to release the product through 
thioester hydrolysis or macrocyclization (Scheme 3).
71
 It has been recently recognized 
that TE domains do not only catalyze the release of the product but, can also catalyze 
other chemistries such as chain elongation, epimerization, Dieckmann or Claisen 
condensation, and deacetylation. The wide deversity of the thioesterase enzyme family 
may lead to novel modification strategies of natural products. 
Elongation by a TE domain is seen in biosynthesis of enterobactin, which is 
known as the strongest siderophore binding feric ions (Fe
3+
) with the affinity K = 10
52
 
M
-1
. The natural product found in Gram-negative bacteria is constructed by NRPS 
enzymes, but it contains trilactone core structure with three identical subunits. It has 
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been shown that the core structure is asembled by the TE domain which covalently binds 
and holds an intermediate on its active site serine residue until another identical unit is 
ready on the neighboring PCP domain.
72
 These two intermediates are condensed 
together on the TE domain, and the new intermediate waits until the next identical unit is 
located on the PCP domain for the second condensation, and finally the trimer molecule 
is released by intramolecualr cyclization to form the trilactone.  
The TE domain NocTE catalyzes epimerization at the final stage of NRPS 
machinaries aquiring nocardicin G which is an intermediate of the β-lactam antibiotic 
nocardicin A produced by the Gram-positive bacterium, Nocardia uniformis subspecies 
Tsuyamenensis.
73
 It was previously proposed that NocTE catalyzed β-lactam formation 
out of the peptide product of five NRPS modules, but NocTE did not recognize any of 
the predicted or activated substrates. It was found that β-lactam formation was achieved 
prior to loading onto NocTE, which subsequently epimerized α-center of the substrate to 
produce nocardicin G.
74
  
TE domains do not only catalyze one additional reaction but may also catalyze 
two additional reactions. For example, the TE domain in a nonreducing PKS Pks1 
catalyzes Claisen/Dieckmann cyclization and deacetylation to synthesize 1,3,6,8-
tetrahydroxynaphthalene (THN), which is a precursor in melanin biosynthesis in the 
fungi Colletotrichum lagenarium. Pks1 consists of the following domains: aceyl-carrier 
protein transacylase (SAT), KS, malonyl-CoA:acyl-carrier protein transacylase (MAT), 
product template (PT), ACP, another ACP, and a TE domain. The TE domain was 
previously known as the Claisen/Dieckmann cyclase class, which was thought to 
catalyze six-membered aromatic ring formation through Claisen/Dieckmann cyclization, 
although formation of the δ-lactone was observed without the TE domain by a reduced 
hydroxyl group and thioester.
75, 76
 The mystery behind construction of THN was that the 
starter unit acetyl group was not incorporated in the product although the SAT domain 
was shown to selectively transfer acetyl group from acetyl-CoA onto the protein.
77, 78
 It 
was finally revealed that the TE domain catalyzed deacetylation in addition to 
cyclization in a single enzymatic step.
79
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Scheme 3. General scheme of product release by TE domain 
 
 
 
 
 
Combinatorial Biosynthesis 
 Three strategies are currently used in combinatorial biosynthesis: precursor-
directed biosynthesis, enzyme-level modification, and pathway-level reconbination 
(Figure 7).
3
 One of the most important properties of many enzymes is substrate 
specificity, but it is not absolute because some enzymes recognize their substrates by a 
part of the structures. When the substrate and its close relatives are not both found in the 
environment, it is not crucial for an enzyme to distinguish between these structures. This 
may result in an enzyme that can accept a relatively broad spectrum of structures and 
may catalyze the following reactions. Precursor-directed biosynthesis describes the 
technique of utilizing this property to produce derivatives of the enzyme’s original 
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product by adding synthetic analogs of the substrate which are chosen by crystal 
structure and computational analysis.
80
 
Enzyme-level modification can be divided into three sub-divisions: domain 
swapping, site-specific mutagenesis, and directed evolution. In each of these divisions, 
mutation or replacement is carried out to alter the specific function of enzyme.
3
 In the 
domain swapping method, a domain of a modular enzyme is replaced with the same type 
of domain from another enzyme to manufacture non-predictable natural products. This 
procedure is often invasive and the yield of the novel product is significantly lowered 
because of the inaccesibility of the intermediate to the following enzymes. The resulting 
mega-protein also tends to become insoluble because of the structure change. This 
problem is resolved by the application of site-specific mutagenesis onto a particular 
sequence of proteins. The mutations are normally performed onto reductive domains 
which do not catalyze backbone construction, but catalyze side chain alteration which 
does not appreciably affect the overal strucrure of the enzyme or the product. The 
directed evolution method is more powerful than site-specific mutagenesis, which does 
not produce a wide variety of derivatives because of the limited scope of mutation. In 
this technique a library of vectors which express randomly mutated proteins is 
introduced into a host organism in which synthesis of the original protein is disrupted. 
The organism then naturally selects acceptable mutations to produce novel natural 
product derivatives. Its multiple outcomes also surpass the domain swapping method 
which produces only one derivative from one successful replacement. 
The most prosperous strategy so far has been pathway-level recombination since 
mederrhodin A was achieved in 1985 which produces a novel compound by 
heterologous expression of biosynthetic genes from separate species.
3
 This procedure is 
not only applied to the novel derivative formation but also utilized for addition of the 
specific substitution on natural product, such as halogenation which has an important 
role in bioactivity of secondary metabolite. It is essential to understand the biosynthetic 
pathway of the original natural product, includeing the function of enzymes, domains, 
and amino acid residues required for its production.  
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Figure 7. Three types of combinatorial biosynthesis 
3
 
 
 
 
AZINOMYCINS 
 
Antitumor Natural Products 
 Azinomycin A and B (1 and 2, Figure 8) are antitumor natural products produced 
by Streptomyces spp., a Gram positive bacteria predominatly found in soil. Azinomycin 
A was originally isolated from Streptomyces sahachiroi as carzinophilin A in 1954. Its 
antitumor activity was identified against Yoshida sarcoma cells, and it was also shown to 
have antibacterial activity against several Gram negative bacteria.
81
 The natural product 
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was reisolated from S. griseofuscus in 1986 with its close structural relatives azinomycin 
B and their derivatives (3-5) which lack the 1-azabicyclo[3.1.0] ring system (Figure 8). 
Azinomycins were subsequently shown to have in vitro cytotoxicity against the mouse 
lymphoma cell line (L5178Y), with a half maximal inhibitory concentration (IC50) of 
0.07 µg/mL and 0.11 µg/mL for azinomycin A and B, respectively. They also showed 
bioactivity against both Gram positive and negative bacteria but not against yeast and 
fungi.
82
 The in vivo antitumor effects in mice were published in the next year. They 
showed positive results agianst Ehrlich carcinoma, where azinomycin A and B had 161 
% and 15 % increase in lifespan (ILS) at a dose of 32 µg/kg/day and 8 µg/kg/day with a 
45 day suvival of 5/8 and 3/8 respectively. They were also effective against P388 
leukemia, where azinomycin B exhibited ILS of 193 % a the dose of 32 µg/kg/day with 
45 days suvival of 4/7. This dosage was much lower than the well known antitumor drug 
mitomycin C which showed 204 % ILS at the 1 mg/kg/day dose with 4/7 survival after 
45 days.
83
 The structures of the azinomycins were determined at the same time, showing 
that they had characteristic epoxide and aziridine ring structures on separate side chains 
with a naphthoate and peptide backbone. The difference between azinomycin A and B 
was found at the peptide end of these structures, where azinomycin B possessed an 
additional enol substituent and a slightly elevated molecular weight of 623 g/mol 
compared to 593 g/mol for azinomycin A. Their structures corresponded to molecular 
formula of C30H33N3O10 and C31H33N3O11, respectively.
84
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Figure 8. Azinomycins and relative compounds 
 
 
 
Mode of Action: Interstrand Cross Link Formation 
 The azinomycins and their related analogs have been shown to induce apoptosis 
of living cells through the formation of sequence specific DNA cross-links in the major 
groove of double stranded DNA. The cross-link is formed by covalent interactions 
between DNA bases and two ring structures of azinomycins, while the naphthoate 
moiety non-covalently interacts with non-polar regions of DNA to enhance the cross-
link formation. It was shown first in 1966 that azinomycin B inhibited DNA synthesis in 
the azinomycin sensitive strain Escherichia coli B0, but neither RNA nor protein 
synthesis were inhibited.
85
 DNA isolated from E. coli and Bacillus subtilis was not 
irreversibly denatured when treated with azinomycin B, suggesting formation of 
interstrand cross-links (ISCs).
86
 This was further confirmed by an ethidium fluorescent 
based investigation which uncovered extensive alkylation and covalent links between 
complementary strands of a variety of short DNA sequences, especially with high G + C 
contents, without modification of the azinomycin structure.
87
 Occurrence of ISC and 
1 
2 
3 4 5 
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alkylation was dependent on low pH, indicating that the basic functional groups on 
azinomycin B were the electrophilic reactive centers. This would also provide some 
specificity for cancer cells, which tend to have a lower pH than healthy cells. 
 Azinomycin B’s (2) sequence specificity was observed by treating 32P labeled 
17-mer synthetic oligonucleotides with the compound and producing cross-links with the 
complementary DNA strands. This was followed by piperidine cleavage of alkylation 
sites and analysis of the scission fragments by polyacrylamide gel electrophoresis. This 
established that the covalent linkage occurred between G and R (A or G) which were 
two base pairs away on each complementary DNA strand (Figure 9-a).
4
 The cross-
linking site of guanine was confirmed as G-N7 by replacement of guanine with 
deazaguanine, which causes complete loss of the activity compared to slight reduction of 
the activity by substituting to inosine. Evidence of the sequence selectivity of 
azinomycin B was added by employing varied triplet (purine-pyridine-pyridine) 
sequences in 15-mer DNA duplex. This determined an optimal recognition sequence of 
5’-d(GCC)-3’ (Figure 9-b).5 The covalent correlation was shown by isolation of 
monoalkylated and cross linked products from the reaction between 4-O-methyl-
azinomycin derivative (6) and self-complementary deoxyoligonucleotide d(TAGCTA)2 
(Figure 9-c).
6
 Monoalkylation was found only at the aziridine ring moiety which 
instantaneously led to the cross-link, indicating two step mechanism was initiated by 
alkylation at the aziridine C10 followed by at the epoxide C21. 
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Figure 9. Sequence selectivity and covalent interaction 
4-7
 
(a) 
(b) (c) 
6 
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 The cellular effects of azinomycin B in vivo were evaluated by cellular 
localization pattern in the yeast Saccharomyces cerevisiae, where fluorescence of the 
naphthoate moiety was visualized as a marker localizing in the cell’s nucleus (Figure 
10). This resembled the behavior of the DNA intercalator, propidium iodide.
8
 Targeting 
of DNA was observed in genomic DNA of treated yeast as significant breakage, and 
transcriptional effects due to DNA damage and repair were displayed by oligonucleotide 
microarrays. Expression of genes involved in DNA synthesis and cell cycle were 
affected, suggesting that the S phase was altered. This was confirmed by a fluorescence 
based cell cycle assay.  
 
 
 
 
 
Figure 10. In vivo action of azinomycin B 
8
 
The results of Affymetrix GeneChip profile were summarized in the cartoon. 
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Mode of Action: Role of Moieties 
 The biological activity of azinomycin analogs has been studied through a 
synthetic approach which led to an understanding of the key moieties present in the 
natural product (Figure 11). An analog consisting of naphthoate, epoxide, and aziridine 
moieties 7 possessed remarkable preference of cross-linking sequence in 15-mer DNA 
duplexes.
88
 The epoxide stereochemistry was responsible for the sequence specificity, 
which was revealed by synthesizing partial structures of azinomycins with four epoxide 
stereoisomers 8-11 showing that only the natural 8 and enantiomeric epoxyamide 9 
formed DNA cross-links and had cytotoxicity. Compound 9 was subsequently found to 
alkylate 3’G in the triplet sequence of nucleotide 5‘-CGG-3‘ instead of 5’G in 5‘-GGC-
3‘ which is preferred by azinomycins.89-91 In the naphthoate epoxyamide structures 8 and 
9, it was critical to preserve both naphthoate and epoxyamide moieties because each 
separate moiety 12-14 failed to react with DNA and was not biologically active.
5, 92
 This 
suggested that the naphthoate moiety also serves an important purpose in interaction 
with DNA. It added evidence to the previously shown data where an azinomycin 
derivative 15 showed reduced cytotoxic activity without the naphthalene ring 16.
54
 Weak 
but significant interaction of the naphthoate moiety with DNA was observed based on 
fluorescence and viscosity measurements by employing the epoxide-broken partial 
structures 17 and 18 in order to avoid the covalent association with DNA.
93
 Removing 
C5’-methyl 19, C3’-methoxy 20, or both of them 21 from the naphthoate ring uncovered 
the significance of methyl group at C5’ position although substituting methoxy 
functional group to ethoxy group also diminished cytotoxicity by an average of 25-
fold.
89, 94
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Figure 11. Azinomycin synthetic analogs for evaluation of the role of naphthoate 
epoxide moiety 
 
 
7 
8 (2S,3S) 
9 (2R,3R) 
10 (2S,3R) 
11 (2R,3S) 
 
 
12 
13 R = OBn 
14 R = NH2 
15 R = CH3 
16 R = 1-naphthalene 
17 R1 = H, R2 = Cl 
18 R1 = p-methoxybenzyl, R2 = OH 
19 R1 = OCH3, R2 = H 
20 R1 = H, R2 = CH3 
21 R1 = H, R2 = H 
 
 29 
 
 Less attention has been paid to the primary alkylating agent, the 
azabicycle[3.1.0]hexane ring, because instability of the structure makes its study 
challenging. Several simple azabicycle analogs 22-31 were synthesized and tested for 
biological activity, but they did not show activity as potent as naphthoate epoxyamide 
analogs. This indicates that the substantially powerful activity of azinomycins results 
from the tandem function of naphthoate, epoxide, and aziridine moieties (Figure 12).
95-98
 
The epoxyaziridine analogs are still largely appealing because of the bisalkylating role 
of two combinatorial cyclic structures which cannot be achieved by the single ring 
structure of epoxyamide analogs. Some potent derivatives were synthesized, and their 
bioactivity was determined. The stereoisomeric derivatives 32 and 33 had IC50 of 2.3 
ng/mL and 3.6 ng/mL respectively against P388 murine leukemia,
95
 and a single ring 
opening from the azabicycle structure 34 showed IC50 of 3.2 ng/mL.
99
 These two 
derivatives displayed higher bioactivity than the azinomycins. A few other relative 
compounds 35-36 were bioactive in <1.0 µM concentrations against the same cell line.95, 
99, 100
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Figure 12. Azinomycin analogs for evaluation of aziridine and epoxyaziridine 
derivatives 
  
 
 
The analog studies inspired some researchers to utilize linkers connecting two of 
the naphthoate epoxyamide 7 so the dimer, including two alkylating agents and non-
polar naphthoate moieties, could form ISC in double stranded DNA like azinomycins 
(Figure 13). Several flexible 37-42 and non-flexible 43-45 linkers were applied and 
22 
23 R = BuO (1R) 
24 R = Bu (1R) 
25 R = BuO (1S) 
26 R = Bu (1S) 
27 R = Et (1R) 
28 R = Et (1S) 
29 R = Bn (1S) 
30 (1R) 
31 (1S) 
 
32 (11R) 
33 (11S) 
 
34 
35 36 
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assessed for ISC formaiton and cytotoxic potencies.
101, 102
 A compound containing the 
flexible linker 42 had the best ISC activity among them showing 70 % of cross-link 
formation within 15-mer oligonucleotide. Compound with linker 38 showed a modest 
activity (40%) while others had much lower bioactivity than these two. Assays targeting 
60 cancer cell lines found that linker 38 possessed significant cytotoxicity with an LC50 
(lethal concentration of 50 % population) of 3.2 µM, which was 11-fold active 
comparing to the monomer compound 7. Linkers 42 and 39 also demonstrated 
cytotoxicity which was more than 2-fold higher than compound 7. Compounds 
synthesized with non-flexible linkers, however, did not have reasonable potency of ISC 
and cytotoxicity. This data suggests that linking an analog with flexible arms of a certain 
length may have promise in terms of developing high bioactivities with easily 
synthesizable units. 
 
 
 
 
Figure 13. Dimeric naphthoate epoxyamides linked by flexible or non-flexible arms 
 
37 linker = –CH2CH2–  
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Biosynthesis: Hybrid Functionality 
 Azinomycin biosynthesis is a fascinating subject to study because its hybrid 
biosynthetic origin, utilizing both PKS and NRPS machinery with an alkaloid derivative 
has been suggested by the structures. The naphthoate and azabicycle ring moieties would 
be derived from a polyketide and an alkaloid, respectively. The skeletal backbone of the 
molecule consisting of ester and amide functional groups could be produced by modular 
NRPSs which would condense the naphthoate moiety and amino acid like substrates. 
The alkaloid-derived azabicyclo[3.1.0]hexane ring is especially captivating because of 
its rarity in natural products. Only a handful of aziridine containing molecules are known 
within more than 100,000 of natural products isolated to date (Figure 14). The 
biosynthetic clusters of some aziridine containing natural products have been proposed, 
but none of the biosynthetic routes have been characterized yet. It has been predicted 
that the structure arises from β-carbon activations, such as halogenation, adenylation, 
sulfonylation, or phosphorylation, followed by condensation of nucleophilic attack of 
nitrogen to the electrophilic carbon. 
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Figure 14. Aziridine containing natural products 
 
 
 
 The PKS origin of the naphthoate moiety was firstly validated through feeding 
isotopic labeled acetate to S. sahachiroi culture followed by 
13
C NMR resonance 
spectroscopy to observe incorporation of the labeled substrate into the azinomycins’ 
structure (Figure 15).
103
 The result showed expected sequential pattern of labeled 
carbons in the naphthoate moiety. This was consistent with PKS mediated biosynthesis 
derived from acetyl- and malonyl-CoA units. The acetate carbons also incorporated with 
C1-C4 of the keto-enol unit and pairs of C6-C7 and C12-C13 in the azabicycle moiety. 
L-Threonine, which is derived from oxaloacetate, was proposed as the substrate of C1-
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C4 unit, and the azabicycle moiety was suggested to be produced from α-ketoglutarate 
derived amino acids, such as glutamate, glutamine, arginine, and proline. The hypothesis 
of the naphthoate origin was supported by another isotopic labeling study which 
deuterated 5-methyl hydrogens of naphthoic acid analogs 46-48, all of whose deuterium 
were detected in 
2
H NMR of resulting azinomycins. This indicated consistent outcome 
that the naphthoic acid is synthesized before introducing into the rest of the molecule 
(Figure 15).
104
 
 
 
 
 
 
 
 
 
Figure 15. Isotopic labeling studies for the origin of the naphthoate moiety 
7
 
 
 
46 47 48 
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 Feeding of isotopic labeled amino acids and their derivatives as NRPS substrates 
showed the skeletal construction of azinomycins (Figure 16). As predicted by the acetate 
feeding observations, L-threonine was confirmed as the substrate of C1-C4 unit of 
azinomycin B by supplementation of 
13
C labeled L-threonine in the culture.
105
 It was 
further demonstrated that other possible intermediates (β-ketoamino acid, β-
hydroxyamino aldehyde, and β-ketoamino aldehyde) acquired from L-threonine did not 
incorporate with the enol moiety. This proposed that the NRPS accepted L-threonine 
without any structural modifications prior to condensation with other units. Azinomycin 
A lacks the enol functional group at C1-C3 position, which suggested a different origin 
from the unit of azinomycin B. This was validated by feeding study of 
13
C labeled 
tentative substrates, such as L-threonine, L-glycine, and aminoacetone.
106
 The result 
displayed significant incorporation of aminoacetone while slight incorporation of L-
threonine and glycine was also observed. This suggested that aminoacetone was the 
direct substrate of the NRPS although it was derived from L-threonine and glycine by 
separate enzymes. These possible homologs were found in S. sahachiroi genome by a 
draft genome sequence. The greater modification of amino acids occurred during the 
epoxide moiety formation, where the α-methyl group of L-valine was oxidized into 
hydroxyl methyl followed by alkene formation in tandem with the replacement of the 
amino acid amine with a carbonyl group. This would enable the substrate to condense 
with PKS derived naphthoic acid.
107
 The most complex unit of azinomycins, azabicycle, 
has been under investigation; however, the current available data strongly suggests the 
glutamate origin that was extensively modified prior to establishment of the skeletal 
substrate. 
 36 
 
 
Figure 16. Biosynthetic origins of azinomycins 
 
 
 
Biosynthesis: Genetics 
 Enzymatic studies were extensively enhanced by uncovering the biosynthetic 
gene cluster of azinomycin B. The informative data was discussed based on homologous 
searches through publicly available database for each gene to theorize functions of 
individual enzymes, and involvement of a type I iterative PKS (AziB) in production of 
the naphthoate moiety was confirmed (Figure 17).
108
 The key genes include five NRPS, 
one PKS, four TE, and many possible alkaloid deriving genes out of more than forty 
total genes. This added strong evidence to the hypothesis of the molecular construction, 
where azinomycins are produced by orchestrated functionality of PKS, NRPSs, and 
alkaloid deriving enzymes. Although most genes have yet to be characterized, there have 
been a few genes identified as essential for the production of azinomycins. Azinomycins 
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were not synthesized when either the NRPS gene aziA2 or an unknown gene aziU3 were 
disrupted.
109, 110
  
The resistance protein against azinomycins, AziR, was identified and 
functionally characterized.
111
 The protein is homologous to aminoglycoside 3’-
phosphotransferase (APH-3’), which is a member of the protein kinase superfamily that 
inactivates aminoglycoside antibiotics. APH-3’ catalyzes phosphorylation on a hydroxyl 
group of the target molecule by γ-phosphate transferred from ATP or CTP. AziR showed 
a protective effect against DNA damage in S. lividans and E. coli caused by azinomycin 
B when the protein was heterologously expressed in these organisms. AziR was not 
active against other aminoglycoside antibiotics probably because it lacks key residues in 
the active site seen in other APH-3’ members, which is proposed to form a salt bridge 
when binding and coordinating with ATP. Understanding of the function and mechanism 
of resistance proteins including AziR could aid the engineered biosynthesis of 
functionally useful anzinomycin analogs in the future. 
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Figure 17. Biosynthetic gene cluster of azinomycins 
 39 
 
STATEMENT OF PURPOSE 
 
 The introductory materials of this chapter highlight the importance of natural 
products and their biosynthesis. High structural diversity of natural products provides 
more options to development of drug therapies. All possible sources on earth have not 
been completely explored. The marine organisms in particular are one of the largest 
unexplored sources. Looking for bioactive natural products in marine sources may 
supply new therapeutic agents or new classes of natural product, which may become a 
basis of many novel drugs. The diversity can be expanded by engineered biosynthesis of 
unnatural natural products. Modular proteins, such as PKSs and NRPSs, have great 
potential for modification, which has already provided many bioactive molecules. For 
more efficient and highly controlled production of these compounds, understanding 
protein function is crucial because seemingly simple catalytic domains are still found to 
possess novel functions. Enzymatic characterization of azinomycin producing proteins 
and evaluation of new natural product from marine source will be discussed in the 
following chapters. 
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CHAPTER II 
 
AZINOMYCIN BIOSYNTHESIS: FORMATION OF THE NAPHTHOATE 
MOIETY BY PKS-TE INTERACTION 
 
INTRODUCTION 
 
 Azinomycins are antitumor agents produced by a soil bacterium, Streptomyces 
sahachiroi as detailed in Chapter I. The structures suggest that these natural products are 
produced by the combination of polyketide synthases (PKSs) and nonribosomal peptide 
synthetases (NRPSs).
84
 The naphthoate moiety is produced by a PKS, while the amide 
bonds and the ester with the naphthoate moiety are constructed by NRPSs. This 
hypothesis is supported by feeding studies identifying the precursors of each moiety and 
bioinformatic studies finding the gene cluster of azinomycins (Figure 16 and Figure 
17).
103-108
 The gene cluster contains more than forty genes including one PKS, five 
NRPS, and four thioesterase (TE) genes. TE domains are known to encode proteins that 
catalyze hydrolysis of thioesters or intermolecular cyclization to release the products 
from PKS or NRPS proteins. TEs consist of families with broad functionalities, 
including coenzymatic activity with PKSs or NRPSs. For example, several TEs are 
known to function by holding an intermediate of a PKS or an NRPS while other 
intermediates are produced. TEs can then combine these intermediates together to build 
the final product.
72, 112
  
The naphthoate moiety has an important role in the interaction of azinomycins 
within the major groove of double stranded DNA. Its hydrophobic property helps 
azinomycins interact with the non-polar region of DNAs, which enhances the antitumor 
activity of the compound.
94
 Antitumor activity was also observed in a partial compound 
which consists of only the naphthoate and epoxide moieties 8, although the naphthoic 
acid 12 itself does not induce apoptosis of cancer cells (Figure 11).
5, 89-92
 Thus, it could 
be applied to cancer therapy as in situ biosynthesis of the active compound. A patient is 
 41 
 
given the non-toxic fragment of the compound 12 and a vector with a cancer specific 
promoter which expresses proteins leading the fragment to a bioactive molecule to treat 
the cancer cells (Figure 18). This chapter will provide insight into the functionality of the 
PKS called AziB and its coenzyme TE called AziG. 
 
 
 
 
Figure 18. In situ biosynthesis of azinomycin analog in target cells 
 
 
 
PRELIMINARY RESEARCH 
 
 The major part of the naphthoate fragment, 3-methoxy-5-methyl-1-naphthoic 
acid, has been hypothesized to be produced by a PKS. This was supported by feeding 
and bioinformatic studies. The feeding study showed that the moiety is produced from 
acetyl carbons of acetyl-CoA and malonyl-CoA which are typical substrates of PKSs.
103, 
104
 The bioinformatic study showed there is only one PKS gene in the gene cluster which 
contains the following domains: ketosynthase (KS), acyl transferase (AT), dehydratase 
(DH), ketoreductase (KR), and acyl carrier protein (ACP) (Appendix Figure 56).
108
 The 
protein also has homologous proteins which produce aromatic natural products 
(Appendix Figure 57).
113-115
 The involvement of the PKS protein, AziB, was further 
supported by the enhanced production of the naphthoate moiety in the presence of 
12 
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additional AziB which was overexpressed in Escherichia coli (Figure 19). The cell free 
extract of S. sahachiroi contains all the soluble molecules of the cells including proteins 
and their precursors. Since malonyl-CoA is used only for the production of azinomycin’s 
naphthoate moiety, [
14
C] labeled malonyl-CoA can be used to measure a change in the 
amount of naphthoate moiety produced. 
 
 
 
 
Figure 19. Enhanced naphthoate moiety production with over expressed AziB (Dr. 
Huitu Zhang) 
The production of the naphthoate moiety was measured as the radiation from [
14
C] 
malonyl-CoA which is incorporated in azinomycin B. 1: Boiled cell free extract + [
14
C] 
malonyl-CoA, 2: Boiled cell free extract + AziB + [
14
C] malonyl-CoA, 3: Cell free 
extract + [
14
C] malonyl-CoA, 4: Cell free extract + AziB + [
14
C] malonyl-CoA. The 
experiment was triplicated (series 1-3). 
 
 
 
 AziB used in the following experiments was heterologously expressed in E. coli, 
and it needed to be posttranslationally modified to produce an active holo-enzyme. All 
ACP domains of PKSs are expressed as a non-active apo-enzyme which is subsequently 
modified with a flexible phosphopantetheinyl arm from coenzyme A on its serine 
residue. This is catalyzed by a phosphopantetheinyl transferase (PPTases).
65
 The 
Series1 
Series2 
Series3 
0 
1000 
2000 
3000 
4000 
5000 
1 2 3 
4 
Naphthoate 
production 
Reaction system 
Activity detection of the purified AziB 
 43 
 
posttranslational modification of AziB was catalyzed by a well established PPTase, Svp, 
found in Bacillus subtilis and two PPTases found in S. sahachiroi (Figure 20).
116
 One of 
the PPTases is associated with fatty acid synthase (FAS) and the other is not. AziB was 
successfully modified by all of the PPTases, but Svp has been used in the following 
experiments to activate AziB because it was able to be overexpressed in a large amount.  
 
 
 
 
Figure 20. Phosphopantetheinylation of AziB with 
3
H-CoA (Dr. Huitu Zhang) 
The posttranslationally modified AziB with radio labeled CoA was assessed by SDS-
PAGE autoradiography. 1: AziB + No PPTase (negative control), 2: AziB + Svp, 3: 
AziB + FA associated PPTase, 4: AziB+ FA non-associated PPTase. 
 
 
 
   The product of AziB was assessed by TLC autoradiography using radiolabeled 
acetyl-CoA and malonyl-CoA. Because the product had been predicted to be 5-methyl-
1-naphthoic acid 49, 1-naphthoic acid was used as a control hypothesizing it should have 
a similar Rf value to the product due to the related structures. The Rf value of the major 
product of AziB, however, was significantly different from the one of 1-naphthoic acid, 
which suggested that the product was in fact not a naphthoic acid (Figure 21-a). The 
product of AziB was subsequently isolated by a preparative TLC, and its structure was 
identified by NMRs and MS analysis as 2-methylbenzoic acid 50 (Figure 21-b).  
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Figure 21. In vitro product of AziB (Dr. Huitu Zhang and Dr. Dinesh Simkhada) 
(a): TLC autoradiography of AziB product with radio labeled substrates. 1: 
14
C acetyl-
CoA, 2: 
14
C malonyl-CoA, 3 and 4: Boiled AziB + labeled substrates, 5 and 6: AziB + 
labeled substrates, 7: 1-naphthoic acid, (b): Purification of AziB product by preparative 
TLC with iodine stain. The major product was identified as 2-methylbenzoic acid. 
 
 
 
 This suggested the involvement of another enzyme in the production of 5-
methyl-1-naphthoic acid since AziB alone produces a different compound, 2-
methylbenzoic acid. It was hypothesized that the curator was a TE because there are 
several TE domains known to function as coenzymes.
72, 73, 79
 It was supported by a LC-
MS study which showed that AziB alone produces a compound with the mass of 2-
methylbenzoic acid (Figure 22-a), but a compound with the mass of 5-methyl-1-
naphthoic acid was produced only when AziG, one of the four TEs in the gene cluster, 
was added in the reaction (Figure 22-b).  
50 
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Figure 22. Induced naphthoic acid synthesis by AziB and AziG (Dr. Dinesh 
Simkhada) 
Reaction with AziB alone (orange line) and AziB+AziG (green line). (a): LC profile at 
the mass 137 m/z, (b): LC profile at the mass 187 m/z. 
 
 
 
RESULTS AND DISCUSSION 
 
Production of 5-Methyl-1-Naphthoic Acid by AziB and AziG 
 The production of the putative 5-methyl-1-naphthoic acid peak by AziB and 
AziG is described in the introduction section above. It was subsequently shown by Dr. 
Dinesh Simkhada that two other TEs in the azinomycin gene cluster, AziA7 and AziA8, 
did not enhance the production of the naphthoic acid (Figure 23-b and Figure 23-c). 
AziA6 was also found to have no involvement in the naphthoic acid production (Figure 
(a) 
(b) 
 46 
 
23-a), which proved that the 187 m/z peak in LC-MS chromatogram was obtained by the 
use of AziG with AziB rather than any of other TEs with AziB. All proteins used in the 
experiments were overexpressed in E. coli using Novagen pET expression vectors. 
These proteins are small, soluble, and relatively stable, thus the pure proteins were easily 
obtained by regular preparation procedures, with the exception of AziA6 which needed 
to be purified by a size exclusion chromatography in addition to the Histidine-tagged 
(His-tag) Ni
2+ 
affinity chromatography (Appendix Figure 58).  
 
 
 
 
Figure 23. LC-MS traces that demonstrate lack of formation of 5-methyl-1-
naphthoic acid by AziA6, AziA7, and AziA8 (Dr. Dinesh Simkhada for AziA7 and 
AziA8) 
 (a): AziA6: blue line: AziB+AziG (control), black line: AziB+AziA6, orange line: AziB 
only (control). (b): AziA7: green line: AziB+AziG (control), blue line: AziB+AziA7, 
orange line: AziB only (control). (c): AziA8: green line: AziB+AziG (control), blue line: 
AziB+AziA8, orange line: AziB only (control). The red arrow shows the production of 
5-methyl-1-naphthoic acid. 
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Comparison to Synthetic Standard of 5-Methyl-1-Naphthoic Acid 
 The synthetic standard of 5-methyl-1-naphthoic acid was synthesized by Dr. 
Dmytro Fedoseyenko, and the structure was further confirmed by 
1
H NMR, 
13
C NMR, 
COSY, HSQC, and HMBC which showed the desired peaks and correlations (Appendix 
Figure 63-Appendix Figure 75 and Appendix Table 5).  
The synthetic standard was analyzed by LC-MS with and without the product of 
the AziB-AziG reaction before being absolutely purified to assess whether there was a 
peak matching the AziB-AziG product. When it was injected alone, there were some 
peaks in the LC profile around the mass of 187 m/z, but none of them matched the peak 
of AziB-AziG product. The apparent mass on the MS profile was slightly different from 
the AziB-AziG product (187.13 m/z for AziB-AziG product and 187.08 m/z for the 
standard). When the standard was co-injected with the AziB-AziG product, however, all 
of the peaks in the LC profile for the standard disappeared while one new peak, which is 
identical to the AziB-AziG product, appeared. In addition, the mass of the peak was the 
same as the one seen in the AziB-AziG MS profile (Appendix Figure 64). It is 
hypothesized that AziB and AziG produce 5-methyl-1-naphthoic acid, but during either 
the reaction or its workup there was a slight modification to the product, which made a 
change in the LC-MS profile.  
The synthetic compound was further purified and treated with the AziB-AziG 
reaction buffer and either acid or base, and it was extracted by the same way as in the 
AziB-AziG reaction before being analyzed in LC-MS (Figure 24). The buffer treatment 
shifts the retention time moderately, and the base extinguishes the second peak which 
was shorter than the first peak and is possibly identical to the synthetic standard without 
treatment. The mass of the sample treated by buffer and base was identical to AziB-
AziG product. This observation suggests that the basic and acidic forms of 5-methyl-1-
naphthoic acid show separate peaks in the chromatogram and slightly different mass in 
the mass spectrometry.  
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Collectively, it was concluded that AziG is responsible for the production of 5-
methyl-1-naphthoic acid in tandem with AziB, which alone produces 2-methylbenzoic 
acid. 
 
 
 
 
Figure 24. LC-MS analysis of AziB-AziG product with the buffer treated standard 
1: Acid + buffer treated, 2: base + buffer treated, 3: buffer treated, 4: no treatment, 5: co-
injection with the AziB-AziG product and base + buffer treated sample. The mass of the 
co-injection sample matches to the mass of the AziB-AziG product. 
 
 
 
AziB-AziG In Vitro Binding Assay 
AziB and AziG have been shown to work in tandem to produce 5-methyl-1-
naphthoic acid. It was evaluated if these two proteins stably bind each other in vitro. For 
the assay His-tag Ni
2+
 affinity column chromatography was used to hold the purified 
AziG while it was washed with S. sahachiroi cell free extract containing all the 
components of the cell residue including AziB. It was shown that there was no AziB 
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found in either the coomassie brilliant blue or the silver stained SDS-PAGE, which 
suggested that the affinity of AziB and AziG is not reasonably high in vitro (Figure 25). 
 
 
 
  
Figure 25. AziB-AziG in vitro binding assay 
Binding affinity of AziB and AziG was assessed in His-tag Ni
2+ 
affinity column 
followed by SDS-PAGE detection with staining by coomassie brilliant blue or silver. C: 
Control (red arrow indicates AziB), 1: concentrated samples, 2: non-concentrated 
samples. 
 
 
 
Bioinformatic Study and Crystal Structure of AziG 
 AziG has been hypothesized by a bioinformatic study including a BLAST search 
as a member of the family of Hotdog fold thioesterase (Appendix Figure 59 and 
Appendix Table 4). The Hotdog fold TE is characterized by the anti-parallel β-sheet as 
the bun wrapping around the long α-helical sausage.117 It forms a functional dimer, and 
two independent active sites are located between these two. One of the homologous 
enzymes of AziG is PaaI found in the phenylacetate degradation pathway in bacteria 
including Escherichia coli.
118
 It is proposed that PaaI hydrolyzes early dead-end 
products of the pathway, such as 2- or 3-hydroxyphenylacetyl-CoA, to salvage CoA.
119
 
The gel filtration chromatography and crystallographic analysis showed that PaaI forms 
a tetramer in which two dimers place their β-sheet buns face to face with each other. 
Comparing to these previously studied thioesterases with a BLAST search, some highly 
conserved regions in the active site had been identified, which were G49, E57, S58, S61, 
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and A62 (Figure 26 and Appendix Figure 60). The E57 residue was predicted to be the 
most critical because this glutamic acid has been shown to covalently bind the carbonyl 
carbon in order to hydrolyze the thioester in the homologous enzymes. A serine residue, 
corresponding to S61 in AziG, then activates a water molecule to release the product as a 
carboxylic acid (Scheme 4-a).
120, 121
 An alternative mechanism includes hydrolytic 
cleavage of enzyme-anhydride intermediate, in which nucleophilic residues including 
aspartic acid, corresponding to E57 in AziG, activate a water molecule to hydrolyze the 
thioester (Scheme 4-b).
122
 This mechanism is found in E73D mutant of 4-HB-CoA 
whose native form catalyzes hydrolysis by the covalent mechanism.
120
 These previous 
studies suggest that the catalytic mechanism of AziG homologous enzymes depends on 
the length of side chain of carboxylate amino acids in the active site. If the side chain is 
long enough (E), the nucleophilic carboxylate can reach the electrophilic carboxyl 
carbon, but if it is not (D), it has to employ a water molecule to reach the reaction site. 
S61 of AziG is not highly conserved in hotdog TEs because it is not necessary when 
they catalyze one-step base catalyzed hydrolysis. The serine is only needed when they 
do two-step reaction where a water molecule is employed for the hydrolysis of enzyme-
anhydride intermediate. AziG is more closely related to the homologous enzymes which 
have the second mechanism. The other serine and histidine residues in the active site of 
some of the homologous Hotdog fold TEs have been shown to be important for their 
optimal activity.
112, 118, 121, 122
 Although there is no direct interaction between the 
substrate and serine or histidine, mutation on these residues significantly affects the 
kinetics. 
 The other possible mechanism is serine hydrolase, which is seen almost all 
characterized TEs for FASs and PKSs (Scheme 4-c).
123-126
 These TEs contain 
characteristic catalytic triad residues within the active site consisting of amino acids Ser-
His-Asp.
126
 It has been proposed that histidine which is stabilized by aspartic acid 
deprotonates serine. The activated serine simultaneously attacks the carbonyl carbon of 
the substrate. The histidine residue again activates a water molecule or a side chain of 
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the substrate to catalyze hydrolysis or cyclization respectively. The amino acid sequence 
analysis, however, could not identify the catalytic triad of Ser-His-Asp in AziG. 
 
 
 
 
Scheme 4. Predicted mechanisms of AziG catalyzed hydrolysis 
(a): Base catalyzed mechanism, (b): hydrolytic cleavage of enzyme-anhydride 
intermediate. (c): Serine hydrolase mechanism 
 
 
 
AziG was crystallized by Dr. Megan D. Sikowitz (Cornell University) to observe 
the detailed peptide structure, particularly in the active site. It was also crystallized with 
the substrate (Figure 26 and Appendix Figure 61). It was shown that AziG forms a 
(a) 
(b) 
(c) 
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tetramer as expected considering homologous enzymes. The tetramer formation was also 
confirmed by gel filtration analysis where native AziG gave calculated mass of 62.2 kDa 
which was significantly close to the theoretical mass of 4 × expressed AziG, 63.4 kDa 
(Appendix Figure 78 and Appendix Figure 79). As predicted by the homologous 
enzymes, it forms functional dimer containing two active sites with approximately 7 Å 
in diameter and 20 Å deep between each monomer unit. Two dimers form a tetramer by 
interaction between each β-sheet bun. The crystal structures validated the bioinformatic 
study for the key residues by displaying the amino acids in the active site and their 
interaction with the substrate. This also added H44 and H48 as study targets. The 
probable binding location of the PPT arm was predicted by alignment with Anthrobacter 
thioesterase with 4-hydroxybenzoyl-CoA (PDB 1Q4U).
120
 From these analyses, it was 
determined that amino acid residues, H44, H48, E57, S58, and S61, were the targets for 
mutation studies. Since all of them can work as a nucleophile, they were mutated into 
alanine to inhibit the nucleophilic function.  
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Figure 26. Sequence alignment of AziG homologs and AziG crystal structures 
(a) Sequence alignment of AziG and its homologs to show the conserved features for the 
substrate binding site. Yellow: the most conserved regions, red: conserved regions, and 
blue: the least conserved regions. (b) Crystal structure of AziG tetramer. (c) Active site 
of AziG with 5-methyl-1-naphthoic acid. (d) Superposition of AziG and 5-methyl-1-
naphthoic acid with Anthrobacter thioesterase with 4-hydroxybenzoyl-CoA (PDB 
1Q4U).
120
 
 
 
 
Site Directed Mutagenesis and Effect to the Production 
 Site directed mutagenesis of the target residues was performed using 
QuikChange II Site-Directed Mutagenesis Kit as described in the Materials and Methods 
section. The mutated expression vectors were produced by PCR with primer pairs 
containing point mutations, and the template WT plasmid was degraded by DpnI 
restriction enzyme which digests methylated DNAs. All plasmids replicated in E. coli 
(a) (b) 
(c) (d) 
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DH10b are naturally methaylated, thus only the PCR product could survive in the 
environment. Since there was no affection on expression and purification of mutants, the 
mutant proteins could be prepared and used for assays in the same manner as wild type 
AziG (Appendix Figure 62).  
 The effect of AziG mutations on the production of 5-methyl-1-naphthoic acid 
was evaluated by LC-MS, which showed that the product was still produced (Figure 27). 
Because some known Hotdog fold TEs activate a water molecule to catalyze hydrolysis 
rather than using a single amino acid to covalently bind the carbonyl carbon of a 
thioester,
122, 127
 it is possible that a water molecule can still interact with the remaining 
amino acids to catalyze the reaction. The kinetics of AziG, however, must be affected by 
the mutations.  
 
 
 
 
Figure 27. LC-MS analysis of AziB-AziG mutant products 
The product of AziB and AziG mutants was analyzed by LC-MS. The wild type AziG 
was used as the control. There was no affect on the production in the AziG mutants. 
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Kinetics of AziG and Its Mutants 
Kinetic parameters of AziG and its mutants for the hydrolysis of 5-methyl-1-
naphthoic acid were measured by using N-acetylcysteamine (NAC)-substrate and 
Ellman’s reagent (5,5'-dithio-bis-(2-nitrobenzoic acid) or DTNB) as described in the 
Materials and Methods section (Figure 28 and Appendix Figure 76). NAC mimics a 
pantetheinyl arm of CoA which allows for a TE recognizing NAC-substrate as its 
target.
128, 129
 The released free thiol is immediately reacted with DTNB to produce mixed 
disulfide and 2-nitro-5-thiobenzoic acid (TNB) which gives a yellow color and absorbs a 
light at 412 nm (Appendix Scheme 5).
130
 The absorbance is proportional to the 
concentration of thiol, which allows measuring the reaction rate of hydrolysis catalyzed 
by TEs.
71
 Because the assay was performed out of the range of the standard buffer for 
the reagent, molar absorptivity was calculated (Appendix Figure 77). Only kcat/Km value 
could be calculated at the low substrate concentrations because the solubility of the 
substrate was highly limited in the aqueous buffer.  
 The kcat/Km value of WT AziG is much lower than homologous hotdog fold 
TEs.
112, 120, 121
 It still shows significant reduction in the kcat/Km values of each amino acid 
mutation, however none of the mutants completely lost their activity and their kinetic 
values were similar to one another. These data are not consistent with any of predicted 
mechanisms although it is clear a mutation on polar residues in the active site affects the 
rate of hydrolysis by AziG. This suggests that interaction with AziB is required for the 
optimal catalytic activity of AziG as an association between AziB and AziG is essential 
for production of 5-methyl-1-naphthoic acid. The rate of hydrolysis by AziG with AziB 
was measured, but it did not produce consistent measurements in the same assay. This 
was probably because the reaction between AziB’s cysteine residues and Ellman’s 
reagent was so robust that it could not be properly eliminated by the control. Although 
the data was not consistent, significant induction of hydrolysis by adding AziB was 
never observed. This suggests that covalently attached product on ACP domain of AziB 
is also necessary for the best activity of AziG. Designing experiments to address these 
issues and to test the hypothesis is currently in progress. 
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Figure 28. Kinetic parameters of AziG and its mutants 
The kcat/Km value of AziG and its mutants was measured at low substrate concentrations 
(0.1, 0.25, 0.4, and 0.5 mM).  
 
 
  
SIGNIFICANCE 
 
 It has been shown that the backbone of the naphthoate moiety, 5-methyl-1-
naphthoic acid, is produced by AziB (PKS) and AziG (TE) in tandem while AziB alone 
produces 2-methylbenzoic acid. The evidence provided by this research strongly 
supports the hypothesis which has been proposed by previous structural, feeding, and 
bioinformatic studies that AziB is responsible for the production of the naphthoate 
moiety. In addition, AziG has been identified as another enzyme involved in the 
naphthoate production. Although the mechanism is yet to be evaluated, the 
bioinformatic, crystallographic, and kinetic studies have shown that AziG is a member 
of the Hotdog fold TE family. The series of experiments discussed here suggest that 
interaction between AziB and AziG is important for both production and release of the 
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product. Understanding the novel tandem work of AziB and AziG sheds new light on 
understanding of PKS-TE interactions. 
 The naphthoate moiety has the other key residue which is a methoxy group at 3’ 
position, which is thought to be produced by catalytic works of a cytochrome P450 
hydroxylase AziB1 and an O-methyltransferase AziB2. Although the 3-methoxy group 
is not as critical as 5-methyl group in non-covalent interaction with DNAs, replacement 
of the methoxy group significantly reduce the cytotoxicity of azinomycin analogs.
89, 94
 
The formation of the ester bond between the naphthoate moiety and the peptide 
backbone is also an interesting aspect of azinomycin biosynthesis relating to the 
naphthoate moiety. There are five NRPS modules in the gene cluster while there are only 
four substrates including 3-methoxy-5-methyl-1-naphthoic acid.
108
 Because 3-methoxy-
5-methyl-1-naphthoic acid and α-ketoisovaleric acid are proposed substrates of AziA1 
(A-PCP domains) and AziA3 (A-KR-PCP domains) respectively,
107, 108
 AziA2 (C-PCP-
C domains) which has additional C and PCP domains has been suggested to be 
responsible for an ester formation between these two acids. It is unclear, however, why 
there needs to be additional C and PCP domains for the condensation of these two 
substrates although the essentiality of AziA2 was shown by the lack of azinomycin 
production by the aziA2 disruption mutant (discussed in Chapter III).
109
 
 Understanding the mechanisms, functions and interactions around the naphthoate 
moiety biosynthesis could lead to a possible application of in situ biosynthesis of a 
bioactive compound in cancer cells where non-toxic substrates and an expression vector 
with a cancer specific promoter are applied to produce a bioactive molecule. It is 
essential for the application that detailed knowledge of toxicity of the related compounds 
and of protein functions is well understood because a minimum number of genes have to 
be used for the effective expression and reaction. This research is one of the important 
first steps for understanding the biosynthesis of azinomycins, including the novel 
interaction of the PKS and the Hotdog fold TE, which will lead to the deeper knowledge 
not only of azinomycin biosynthesis but also of entire natural product biosynthesis. 
 
 58 
 
MATERIALS AND METHODS 
 
General Experimental Procedure 
LC-MS was carried out on a Bruker MicroTOF-QII mass spectrometer (Billerica, 
MA, USA) coupled to an Agilent 1200 Infiniti series liquid chromatography system 
(Agilent Technologies, Santa Clara, California, USA) with a Prodigy 5 µm ODS-2 150 
Å, LC Column 250 x 4.6 mm (Phenomenex, Torrance, California, USA). NMR spectra 
were acquired in CDCl3 or CD3OD with a Varian Mercury 300 spectrometer or Bruker 
Advance III 500 MHz spectrometer equipped with a 5 mm H-C-N cryoprobe. UV light 
absorption was measured by GENESYS 2 UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). Gel filtration chromatography was 
performed with Superdex 75 PC HiLoad 16/60 (GE Healthcare, Little Chalfont, UK) at 
the Protein Chemistry Laboratory at the Texas A&M Univeristy. 
 
Reagents and Materials  
 Streptomyces sahachiroi (NRRL 2485) was obtained from the American Type 
Culture Collection (ATCC). Cloning steps were performed in E.coli DH5α or E.coli 
TOP10. E.coli Rosetta (DE3) or E.coli BL21 (DE3) was used for protein expression. 
PCR was performed using Phusion High-Fidelity DNA Polymerase (New England 
BioLabs). Plasmids used for gene expression were pET-24a(+) and pET-21-d(+) 
purchased from Novagen. Plasmid preparation and DNA purification were carried out 
using commercial kits (Qiagen). Restriction enzymes and other molecular biology 
reagents were from commercial sources (BioLabs). Unlabeled coenzyme A (CoA), 
acetyl coenzyme A, malonyl coenzyme A substrates, β-Nicotinamide adenine 
dinucleotide phosphate reduced form (NADPH), S-(5’-Adenosyl)-L-methionine chloride 
(SAM), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), and chemicals used in organic 
synthesis were purchased from Sigma-Aldrich. 5-Bromo-1-naphthoic acid was 
purchased from Ark Pharm, Inc. (Libertyville, IL, USA). The deuterated solvents for 
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NMR experiments were purchased from Cambridge Isotope Laboratories, and all other 
solvents were purchased from Fisher Scientific at highest available grade. 
 
Cloning of AziA6 into an Expression Vector for E. coli 
 A thioesterase gene, aziA6, was amplified from genomic DNA of S. sahachiroi 
by PCR with primers AziA6-F and AziA6-R. The PCR reaction was performed in a 25 
μL reaction mixture consisting of: 0.5 µL Phusion High-Fidelity DNA polymerase, 4 µL 
Phusion GC Buffer, 15 ng of S. sahachiroi genomic DNA, 0.5 µL of each 20 mM 
forward and reverse primer, 0.5 µL of 20 mM dNTP, 1.25 µL of DMSO, and water to a 
total volume of 25 µL. The PCR condition was optimized as following: initial 
denaturation for 30 s at 98 
o
C, 25 cycles of 10 s at 98 
o
C, 20 s at 75 
o
C, and 1 min at 72 
o
C, and a final extension for 10 min at 72 
o
C. The DNA fragment of aziA6 was purified 
by agarose gel extraction using QIAquick Gel Extraction Kit (Qiagen, Venlo, 
Netherlands), and it was digested by restriction enzymes HindIII and XhoI. After 
purified by agarose gel extraction again, the DNA fragment was ligated into 
HindIII/XhoI multiple cloning site of an expression plasmid vector pET-24b (EMD 
Millipore, Billerica, Massachusetts, USA) which contains 6xHis-tag at the 3’-end. The 
resulted plasmid pET24b-aziA6 was transformed into an E. coli strain TOP10 by 
electroporation, which was cultured on solid LB medium with 50 µg/mL of kanamycin 
overnight. Each colony was subsequently cultured in 5 mL of LB medium with the 
antibiotic overnight for plasmid isolation by QIAprep Spin Miniprep Kit (Qiagen). 
Cloning of the gene was confirmed by sequencing reaction using BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, California, USA). The 
cloned plasmid was transformed again into an E. coli expression strain BL21(DE3) for 
overexpression. 
 
Site Directed Mutagenesis of AziG 
 Cloning of aziG was carried out by a former lab mate Michelle Lebo, where aziG 
was inserted into pET-24b multiple cloning site (pET-24b-aziG) and was transformed 
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into BL21(DE3). H44, H48, E57, S58 and S61 of AziG were mutated to alanine using 
QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, 
California, USA). Primers containing point mutations were used to amplify mutated 
plasmids for each. Primer pairs for H44A, H48A, E57A, S58A, and S61A mutations 
were AziG-H44A-F and AziG-H44A-R, AziG-H48A-F and AziG-H48A-R, AziG-
E57A-F and AziG-E57A-R, AziG-S58A-F and AziG-S58A-R, and AziG-S61A-F and 
AziG-S61A-R, respectively. PCRs were performed as the following program: initial 
denaturation for 30 s at 95 
o
C and 12 cycles of 30 s at 95 
o
C, 1 min at 55 
o
C, and 6 min at 
68 
o
C. The amplified plasmids were treated with DpnI restriction enzyme for 3 hours to 
degrade methylated DNA naturally produced by E. coli. The mutated plasmids were 
transformed into DH10b by electroporation, and the mutations were confirmed by 
sequencing reactions after isolating the plasmids from the strains. The plasmids were 
subsequently transformed into BL21(DE3) for overexpression. 
 
Overexpression of AziB, Svp, AziA6, AziG, and AziG Mutants 
 AziB, Svp, AziA6, AziG, and AziG mutants were overexpressed in the same 
manner. E. coli strains which contain their expression plasmids were cultured in 5x5 mL 
LB media for AziB, 3x5 mL for Svp, 4x5 mL for AziA6, and 2x5 mL for each AziG 
overnight with proper antibiotics, which are 50 µg/mL kanamycin for AziB, AziA6, and 
AziGs and 100 µg/mL ampicilin for Svp. Each of the 5 mL overnight cultures was 
inoculated into 1 L LB medium and grown until OD600 reaches 0.6-0.8. The production 
of the proteins was induced by 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
incubation in 16 
o
C at 250 rpm for 22 hours. The resulted cells were harvested by 
centrifugation at 7000 rpm for 15 min. After discarding the supernatant, the cells were 
washed with 250 mL of DI water and centrifuged down again by the same condition. 
The supernatant was discarded, and the cells were washed again with 30 mL of AziB-
Svp reaction buffer (75 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 5 mM dithiothreitol 
(DTT), and 20% glycerol). It was centrifuged down again at 9900 rpm for 15 min, and 
the supernatant was discarded. The remaining steps were performed on ice. The cells 
 61 
 
were resuspended into the AziB-Svp reaction buffer of 30 mL for AziA6 and each AziG 
and total 100 mL for AziB and Svp which were subsequently mixed together. 
Phenylmethanesulfonylfluoride (PMSF) was added into each solution to the final 
concentration of 1 mM shortly before the cells were lysed by sonication with Branson 
Sonifier 450 (Branson Ultrasonics, Danbury, CT) fitted with a 5 mm micro-tip, output 
setting 6, duty cycle 60%, and 5 cycles for 30 sec each. The lysed cells were removed by 
centrifugation at 9900 rpm for 45 min twice to remove the cell residues completely. The 
supernatants which consist of water soluble proteins were stored in 4 
o
C. 
 
Posttranslational Modification of AziB with Svp and Coenzyme A 
  Approximately 90 mL of apo-AziB and Svp crude protein extract was obtained 
following cell lysis and centrifugation. Apo-AziB was converted to the holo-form by 
adding 5 µmol of coenzyme A, giving a final concentration of ~5.5 µM.  The sample 
was incubated at 28 
o
C, 250 rpm for 1 h. Any resulting precipitation formed during 
incubation was removed by centrifugation, 9900 rpm for 45 min. Holo-AziB/Svp were 
purified by nickel affinity chromatography. A HisTrap FF 5 mL column was equilibrated 
with PPT buffer and subsequently loaded with the protein mixture at a rate of 0.25 
mL/min. The column was washed with 200 mL of PPT column buffer (1 mM DTT, 500 
mM NaCl, 40 mM imidazole, 75 mM Tris-HCl, pH 8.0, and 20％ glycerol) and eluted 
with 30 mL of PPT column buffer supplemented with 250 mM imidazole. The buffer 
was exchanged to the AziB-AziG reaction buffer (50 mM potassium phosphate, pH 7.5, 
and 20 % glycerol).  The purity and quantity of holo-AziB and Svp were assessed by 8 
% (v/v) SDS-PAGE and Bradford assay utilizing the Bio-Rad Protein Assay kit (Bio-
Rad Laboratories, Hercules, CA, USA); bovine serum albumin (BSA) was implemented 
as a standard. 
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Purification of AziB-Svp, AziA6, AziG, and AziG Mutants 
The crude solutions, which contained AziA6 or AziGs were applied to pre-
equilibrated HisTrap FF 5 mL columns at 0.25 mL/min. The loaded columns were 
treated as follows: 
 For AziA6, the column was washed with 200 mL of column buffer supplemented 
with 40 mM imidazole, and eluted with 30 mL of column buffer supplemented 
with 250 mM imidazole 
 For AziG and its mutants the column was washed with 200 mL of column buffer 
supplemented with 60 mM imidazole and eluted with 30 mL of column buffer 
supplemented with 250 mM imidazole 
The buffer was exchanged to AziB-AziG reaction buffer (potassium phosphate: 50 mM, 
glycerol: 20 %, pH 7.5) by centrifugal ultrafiltration units for 10 kDa (Amicon Ultra - 
15) except for AziA6. An additional purification step was required for AziA6. The 
buffer was exchanged to sephadex column buffer (20 mM sodium phosphate, 150 mM 
NaCl, pH 7.5). The sephadex G-50 fine (size exclusion) column with 200 mL volume 
about 1 m height was equilibrated with the sephadex column buffer. The AziA6 solution 
was concentrated as the total volume reached 1.5 mL which was loaded into the column, 
and fractions were collected every 3 mL which were later analyzed for quantity and 
purity by Bradford assay and 12% (v/v) SDS-PAGE. The purified AziA6 fractions were 
combined together and the buffer was exchanged to AziB-AziG reaction buffer. 
 
In Vitro Synthesis of 5-Methyl-1-Naphthoic Acid by AziB and TE Domains 
 A 25 mL of the reaction solution consists of 50 µM of acetyl coenzyme A, 250 
µM of malonyl coenzyme A, 10 µM of NADPH, about 10 mg of AziB-Svp mixture, and 
about 10 mg of AziA6 or AziG in the AziB-AziG reaction buffer. The reaction solution 
was incubated in 30 
o
C overnight. The product was cleaved from the protein by 
basification of the solution with NaOH till pH about 12, and it was subsequently 
acidified by HCl till pH below 5 for the following extraction. The acidified product was 
extracted with the equal volume of ethyl acetate three times. After dried over anhydrous 
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sodium sulfate, ethyl acetate was evaporated off in vacuo and gentle flow of dry nitrogen 
gas. In case of AziG mutant assays, the solution after the reaction was neither basified 
nor acidified. Alternatively, the reaction solution was filtered out with centrifugal 
ultrafiltration units for 3 kDa, and the filtrate was extracted with the equal volume of 
ethyl acetate three times and solidified by the same method. 
 
LC-MS Analysis of AziB and AziA6 or AziG Products 
 The product was analyzed by LC-MS. It was dissolved in 100 µL of methanol, 
and 10-30 µL of the sample was injected into the reversed-phase HPLC column 
(Phenomenex, Columbus 5μ C8 100A, 250 x 3.20 mm 5 μ) which was pre-equilibrated 
with 80% A (water) and 20% B (75% methanol and 25% isopropanol). The liquid 
chromatography was ran by the following program: Time 0 min A-80% B-20%; 1 min 
A-80% B-20%; 15 min A-0% B-100%; 30 min A-0% B-100%; 32 min A-80% B-20% 
till 40 min at the flow rate 0.75 µL/min. It was monitored by UV at 254 nm wavelength 
and by mass at around 136 m/z (2-methylbenozoic acid) and 187 m/z (5-methyl-1-
naphthoic acid).  
 
Synthesis of 5-Methyl-1-Naphthoic Acid (Dr. Dmytro Fedoseyenko) 
tert-butyl-5-bromo-1-naphthoate 52
131
 
Oxalyl chloride (0.4 mL) was added to a suspension of 5-bromo-1-naphthoic acid 
51 (1.08 g) in dichloromethane (9.3 mL) containing 3 drops of dimethylformamide and 
the reaction mixture was stirred at ambient temperature for 6 h. The solution was 
concentrated to afford a white solid, which was re-dissolved in tetrahydrofuran (THF).  
The solution was cooled to 2 
o
C and a solution of potassium tert-butoxide (0.72 g) in 
THF (14.8 mL) was added dropwise, which was stirred at ambient temperature for 3 h. 
The solution was poured onto ice (20 g) and extracted with ethyl acetate (2 x 10 mL). 
The combined organic extracts were washed with water (10 mL), dried over sodium 
sulfate, and concentrated in vacuo. The residue was purified by flash column 
chromatography (cyclohexane:ethyl acetate = 1:1) to give 5-bromo-1-naphthoic acid 
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tert-butyl ester 52 in 91 % yield (12 g). 
1
H NMR (300 MHz, CDCl3): δH 8.86 (d, J = 9.0 
Hz, 1H), 8.48 (d, J = 8.7 Hz, 1H), 8.13 (dd, J = 7.3, J = 0.9 Hz, 1H), 7.86 (dd, J = 7.5, J 
= 0.9 Hz, 1H), 7.62 (dd, J = 8.6, J = 7.5 Hz, 1H), 7.45 (dd, J = 8.7, J = 7.5 Hz, 1H), 1.71 
(s, 9H). 
 
tert-butyl-5-methyl-1-naphthoate 53
132
 
To a solution of 5-bromo-1-naphthalene-1-carboxylic acid tert-butyl ester 52 
(1.00 g, 3.26 mmol) in THF (10 mL), -78 
o
C, was added n-butyllithium (2.5 M in 
hexanes, 1.56 mL) over a period of 2 min. After stirring for 40 min, methyl iodide (0.55 
g) was added. This reaction mixture was allowed to warm to room temperature over 1.5 
h.  The reaction was quenched with water (10 mL) and partitioned between water and 
diethyl ether (3 x 50 mL). The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. Purification of the residue by flash-chromatography 
(hexanes:EtOAc = 98:2) gave compound 53 in 84% yield (660 mg). 
1
H-NMR (300 
MHz, CDCl3): δH 8.70 (d, J = 8.7 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 8.07 (dd, J = 7.3, J 
= 1.2 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.54-7.48 (m, 1H), 7.42-7.37 (m, 1H), 2.75 (s, 
3H), 1.72 (s, 9H). 
 
5-methyl-1-naphthoic acid 49
132
 
  5-Methynaphthalene-1-carboxylic acid tert-butyl ester 53 (1.37 g, 4.45 mmol) 
was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (3 mL) was added. 
After stirring for 16 h, the reaction was concentrated in vacuo to give compound 49 in 
quantitative yield.  
1
H-NMR (300 MHz, CD3OD): δH 8.73 8.74 (d, J = 8.7 Hz, 1H), 8.28 
(d, J = 8.4 Hz, 1H), 8.18 (dd, J = 7.2, J = 1.2 Hz, 1H), 7.58 (dd, J = 8.5, J = 7.2 Hz, 1H), 
7.52-7.44 (m, 1H), 7.44-7.36 (m, 1H), 2.73 (s, 3H). 
13
C NMR (125 MHz, CD3OD): δC 
20.0, 125.0, 125.5, 125.8, 128.0, 128.1, 130.0, 130.4, 132.6, 134.3, 135.9, 171.5. MS 
(ESI): m/z calculated for [M-H+] C12H9O2 185.0603, found 185.0611. 
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LC-MS Analysis of AziB-AziG Product with the Synthetic Standard 
 Synthetic 5-methyl-1-naphthoic acid was acquired by Dr. Dmytro Fedoseyenko 
(Dr. Begley group, Texas A&M University), and the structure was further confirmed by 
1
H NMR, 
13
C NMR, COSY, HSQC, and HMBC. The synthetic compound was treated 
with acid, base, or nothing followed by the AziB-AziG reaction buffer, and it was 
extracted and dried by the same method as previously described. Those three samples 
and untreated compound were analyzed by LC-MS in the same way as described in the 
last section. The base treated sample had a single peak which was also shown in the 
AziB-AziG product analysis, and the identity of the two peaks was confirmed by co-
injection.  
 
Preparation of Cell Free Extract of S. sahachiroi 
 Cell free extract of S. sahachiroi was prepared from 5 L fermentation culture 
with the previously described procedure.
105
 After 72 h fermentation, the cells were 
harvested by centrifugation at 7000 rpm for 15 min, which were washed with 1.5 L of 
water twice and with 250 mL of the His-tag binding buffer once. The cell pellet was 
divided by half and frozen at -80 
o
C. The cells were resuspended in 50 mL of the His-tag 
binding buffer and placed in the bead beater cabinet with 0.1 mm glass beads. The cell 
membranes were disrupted by ten times of 1 min run with 5 min interval on ice to ensure 
everything was kept ice cold. The disrupted cell residues were removed by 
centrifugation at 12,000 rpm for 45 min twice. The supernatant was kept for AziB-AziG 
in vitro binding assay. 
 
AziB-AziG In Vitro Binding Assay 
 AziG-AziB binding assay was carried out on His-tag Ni
2+
 affinity column. AziG 
was loaded onto the column as described in the previous section (Purification of AziB-
Svp, AziA6, AziG, and AziG mutants), and the cell free extract was passed through the 
column at the same rate as loading AziG. The column was subsequently washed with 
200 mL of the His-tag buffer with 60 mM imidazole, and the proteins were eluted with 
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30 mL of the buffer with 250 mM imidazole. The elution was concentrated to 1 mL by a 
centrifugal filter unit for 100 kDa. The proteins were assessed by SDS-PAGE following 
to coomassie blue and silver stains with Silver Stain Plus
TM
 Kit (Bio-Rad, Hercules, 
California, USA).  
 
Gel Filtration Chromatography of AziG Native Form 
Mass of the native state AziG in solution was assessed by gel filtration (size-
exclusion) chromatography. Approximately 1 mg of each protein sample was injected 
into a pre-equilibrated (10 mM phosphate and 150 mM NaCl at pH 7.2) gel filtration 
column (Superdex 75 PC HiLoad 16/60, GE Healthcare) at room temperature. The 
elution volume was measured by detecting the sample elution with UV absorbance at 
280 nm. The calibration curve was generated by chromatography with following 
protein standards: bovine serum albumin (molecular mass, 67 kDa; elution volume, 55.6 
mL), ovalbumin (45 kDa; 61.0 mL), carbonic anhydrase (29 kDa; 69.2 mL), and 
cytochrome C (13 kDa; 81.6 mL) (Appendix Figure 78-a). Plotting elution volume (mL) 
vs. molecular mass of standard (kDa) gave a linear trend line with the following equation 
(Appendix Figure 79): 
                   
The elution volume of native AziG was 55.6 mL, thus the molecular mass was 
calculated as 62.2 kDa (Appendix Figure 78-b). Since the theoretical mass of expressed 
AziG (containing plasmid restriction site and 6 x Histidine) is 15.8 kDa, it is predicted 
that the native state of AziG in solution is that of a tetramer (± 1.61 % error). 
 
Crystallization of AziG (Dr. Megan D. Sikowitz) 
The hanging drop vapor diffusion method was used for crystallization. In this 
method, the frozen protein aliquots were thawed on ice and equal volumes of protein and 
reservoir solution were mixed and equilibrated at 22 °C against a total volume of 500 μL 
well solution. Using the commercially available sparse matrix Wizard screens (Emerald 
Biosystems), three crystallization conditions were identified.  Crystals were observed in 
 67 
 
Wizard I condition 13 (1.32 M ammonium sulfate and 0.1 M cacodylate pH 6.5), Wizard 
II condition 39 (0.1 M CAPS pH 10.5, 0.2 M NaCl, and 20% PEG 8,000), and Wizard 
III condition 33 (1.6 M magnesium sulfate and 0.1 M MES pH 6.5). Optimized crystals 
grew in 1.25 M ammonium sulfate and 0.1 M cacodylate pH 6.0, 1.6 M magnesium 
sulfate and 0.1 M MES pH 5.5, or 0.1 M CAPS pH 10.8, 0.2 M NaCl, and 14% PEG 
8000. In all three conditions, crystals with similar morphologies appeared overnight. The 
crystals were square bipyramidal, 60 μm long, and about 40 μm in width at the center.  
The crystals were cryprotected for data collection in a solution composed of their mother 
liquor supplemented with 15% (v/v) glycerol before flash freezing in liquid nitrogen. For 
soaking experiments, the crystals were soaked with 10 mM 3-hydroxy-2-NPA for 5 min 
before cryoprotection and flash freezing. 
 
X-Ray Data Collection and Processing (Dr. Megan D. Sikowitz) 
X-ray diffraction experiments were conducted at CHESS (Cornell High Energy 
Synchrotron Source) beamline F1 using a Q270 detector (Area Detector Systems Corp.) 
at a distance of 304.7 mm and wavelength of 0.91830 Å. The oscillation method was 
used with 1º rotation per frame for 90º with cryocooling and 10 s exposures. Crystals 
grown in all three conditions were tested for diffraction quality. The data sets reported 
are for crystals grown in the ammonium sulfate containing condition. Additional 
diffraction experiments on the ligand soaked crystals were conducted at APS NE-CAT 
beamline 24-ID-E (Argonne National Laboratory) using a Quantum 315 detector (Area 
Detector Systems Corp.) at a distance of 325 mm and wavelength of 0.97919 Å. The 
oscillation method was also used, with 1º rotation per frame for 70º with cryocooling and 
1 s exposure time.  HKL2000 was used for indexing, integration, and data scaling.
133
 
Complete data collection and refinement statistics are listed in Appendix Table 6.  
 
Structure Determination, Model Building, and Refinement (Dr. Megan D. Sikowitz) 
The AziG crystal belongs to space group I4122 and contains one promoter per 
asymmetric unit.  It has a Matthew’s coefficient of 2.73 Å3/Da with corresponding 
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solvent content of 54.9%. The structure of AziG was determined using the molecular 
replacement method, with Mycobacterium tuberculosis thioesterase (PDB ID: 3S4K) as 
the model. The program Chainsaw was used to create a search model from 3S4K. 
Molecular replacement using this search model was conducted with MolRep. Iterative 
rounds of model building were conducted with COOT, with refinement using RefMac5 
in initial rounds, and PHENIX.refine in final rounds.  The quality of the final structure 
was assessed using MolProbity. The final structure refinement was completed with an R-
factor value of 22.2% and Rfree of 26.6%. This structure was used as the model for 
refinement of the SsAziG/3-hydroxy-2-NPA structure. PHENIX.elbow was used for 
ligand generation before placement into Fo − Fc electron density. Model improvement of 
the liganded structure was performed as described above. Structure refinement for 
SsAziG/3-hydroxy-2-NPA converged with an R-factor of 20.2% and Rfree of 25.0%. 
Complete refinement statistics for both structures are listed in Appendix Table 6. 
 
Kinetics of AziG Hydrolysis 
 The kinetic parameters of AziG and its mutants were measured as the formation 
of 2-nitro-5-thiobenzoic acid (TNB) at 412 nm (ε = 8,857.1 M-1cm-1) followed by the 
reaction of 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB or Ellman’s reagent) with a free 
thiol produced by hydrolysis of 5-methyl-1-naphthoate-SNAC by AziGs. 5-methyl-1-
naphthoate-SNAC was synthesized by Dr. Dmytro Fedoseyenko, and the absorbance 
was measured on GENESYS
TM
 2 UV-Vis Spectrometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). The reaction was carried out in the AziB-AziG reaction 
buffer without glycerol, which contains 0.4 mM of DTNB, 20 µM of AziGs, 0.1-0.5 mM 
of the substrate, and 5% DMSO.  
Three types of buffered solutions consisting of DTNB alone, AziG + DTNB, or 
substrate + DTNB were used to establish a control because DTNB and the substrate are 
chemically degraded by water molecules and AziG contains cysteine residues, which can 
react with DTNB. The effect of chemical degradation of DTNB which was counted 
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twice on the absorbance of two solutions (AAziG-DTNB and Asubstrate-DTNB) can be 
eliminated for utilizing the following equation: 
Acontrol = AAziG-DTNB + Asubstrate-DTNB – ADTNB 
The control was used to correct these undesired effects with the following equation: 
Acorrected = AAziG+substrate+DTNB – Acontrol 
The absorbance was observed continuously every 30 s, and the rates of 
hydrolysis were determined from the initial linear component of the curves. The assays 
were performed at least 4 times for each data point. 
DMSO was used to solubilize the substrate. Since the solubility was highly 
limited even in 5% DMSO, however, the velocity could be calculated only in low 
substrate concentrations. Therefore, the limited case of Michaelis–Menten kinetics 
where [S] << [Km] was applied to obtain kcat/Km values as the slopes of plotted linear 
graph of V/[E] vs. [S] by the following equation: 
 
   
 
    
  
    
where V is velocity, [E] is concentration of AziGs, and [S] is concentration of the 
substrate. 
 
Molar Absorptivity of TNB 
 Absorbance at 412 nm of TNB with different concentrations of free thiol in the 
buffer used in kinetic experiments was measured as the product of the reaction with 
DTNB and N-acetylcysteamine (NAC). The solution contains 50 mM potassium 
phosphate, 0.4 mM DTNB, 5% DMSO, and varied (10, 20, 30, 40, 50, and 60 µM) 
concentrations of NAC, and the absorbance at 412 nm was measured on GENESYS
TM
 2 
UV-Vis Spectrometer. The molar absorptivity of TNB was calculated by Beer-Lambert 
law: 
A = εcl 
where A is the absorbance, ε is the molar absorptivity (M−1 cm−1), c is concentration 
(M), and l is the pathlength (cm). Since the pathlength is 1 cm, the molar absorptivity 
was calculated as a slope of a linear graph of A vs. c, which was 8,860 M
−1
 cm
−1
. 
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Synthesis of 5-Methyl-1-Naphthoate-SNAC Ester (Dr. Dmytro Fedoseyenko) 
S-(2-acetamidoethyl) 5-methylnaphthalene-1-carbothioate 54  
5-methyl-1-naphthoic acid 49 (55 mg, 0.3 mmol), (3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (114 mg, 0.6 mmol), DMAP (37 mg, 0.3 mmol), N-
acetylcysteamine (SNAC) (35 mg, 0.3 mmol) and triethylamine (60 mg, 0.6 mmol) were 
stirred in dichloromethane (10 mL) under argon at room temperature overnight. The 
organic layer was washed with saturated NaHCO3 solution, 0.1 N HCl solution and brine 
(10 mL of each).  It was dried over anhydrous sodium sulfate, concentrated in vacuo and 
purified by flash column chromatography (dichloromethane) to provide pure white solid 
product in 81% yield (70 mg). 
1
H NMR (300 MHz, CDCl3): δH 1.99 (s, 3H), 2.71 (s, 
3H), 3.27 (t, J = 6.3 Hz, 2H), 3.59 (q, J = 6.3 Hz, 2H), 6.11 (s, 1H), 7.38 (d, J = 7.2 Hz, 
1H), 7.44 – 7.55 (m, 2H), 8.01 (d, J = 7.2 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 
8.7 Hz, 1H). 
13
C NMR (75 MHz, CDCl3): 195.05, 170.4, 135.7, 134.7, 132.9, 129.2, 
129.0, 127.7, 127.5, 127.3, 124.3, 123.2, 39.7, 29.5, 23.3, 19.8. MS (ESI): m/z calculated 
for [C16H17NO2S + Li
+
] 294.1140, found 294.1134 
 
 
 
Table 1. Primers used in Chapter II 
AziA6-F 5’-GTCAAGCTTATGGACTCGCCCTGGGTGCGCCGC-3’ 
AziA6-R 5’-GAGCTCGAGCGAAGAGGTCCTTCCGGCCGGAGC-3’ 
AziG-H44A-F 5’-GCAGTATCCCGGCAGGCTGCAGCAGGTCGG-3’ 
AziG-H44A-R 5’-CCGACCTGCTGCAGCCTGCCGGGATACTGC-3’ 
AziG-H48A-F 5'-TGCACCCCGCCGGCCAGTATCCCGTGAGGC-3' 
AziG-H48A-R 5'-GCCTCACGGGATACTGGCCGGCGGGGTGCA-3' 
AziG-E57A-F 5'-GCGCTGTGGTCGCGTCCGTCGCCAG-3' 
AziG-E57A-R 5'-CTGGCGACGGACGCGACCACAGCGC-3' 
AziG-S58A-F 5'-CGCTGGCGACGGCCTCGACCACAGC-3' 
AziG-S58A-R 5'-GCTGTGGTCGAGGCCGTCGCCAGCG-3' 
AziG-S61A-F 5'-GAGTCCGTCGCCGCCGCGGCAGCGGA-3' 
AziG-S61A-R 5'-TCCGCTGCCGCGGCGGCGACGGACTC-3' 
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Table 2. Strains and plasmids used in Chapter II 
E. coli TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 
galE15 galK16 rpsL(Str
R) endA1 λ- 
Invitrogen 
E. coli 
TOP10/pET-
24b-aziA6 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 
galE15 galK16 rpsL(Str
R) endA1 λ-with AziA6 
expression plasmid 
This study 
E. coli DH10B F
-
 endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 
Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA 
Δ(mrr-hsdRMS-mcrBC) λ- 
Invitrogen 
E. coli 
DH10B/pET-
aziG-H48A 
F
-
 endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 
Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA 
Δ(mrr-hsdRMS-mcrBC) λ- with AziG H48A 
expression plasmid 
This study 
E. coli 
DH10B/pET-
aziG-E57A 
F
-
 endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 
Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA 
Δ(mrr-hsdRMS-mcrBC) λ- with AziG E57A 
expression plasmid 
This study 
E. coli 
DH10B/pET-
aziG-S58A 
F
-
 endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 
Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA 
Δ(mrr-hsdRMS-mcrBC) λ- with AziG S58A 
expression plasmid 
This study 
E. coli 
DH10B/pET-
aziG-S61A 
F
-
 endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 
Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA 
Δ(mrr-hsdRMS-mcrBC) λ- with AziG S61A 
expression plasmid 
This study 
E. coli 
BL21(DE3) 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) Invitrogen 
E. coli 
BL21(DE3)/ 
pET-24b-aziA6 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziA6 expression plasmid 
This study 
E. coli 
BL21(DE3)/ 
pET-24b-aziG 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziG expression plasmid 
This study 
E. coli 
BL21(DE3)/ 
pET-aziG-H44A 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziG H44A expression plasmid 
This study 
E. coli 
BL21(DE3)/ 
pET-aziG-H48A 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziG H48A expression plasmid 
This study 
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Table 2 Continued 
E. coli 
BL21(DE3)/ 
pET-aziG-E57A 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziG E57A expression plasmid 
This study 
E. coli 
BL21(DE3)/ 
pET-aziG-S58A 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziG S58A expression plasmid 
This study 
E. coli 
BL21(DE3)/ 
pET-aziG-S61A 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziG S61A expression plasmid 
This study 
E. coli 
BL21(DE3)/ 
pET-24a-aziB 
B; F−ompT hsdSB(rB− mB−) gal dcm (DE3) with 
AziB expression plasmid 
This study 
pET-24a E. coli expression vector, Km
r
 Novagen 
pET-24b E. coli expression vector, Km
r
 Novagen 
pET-24b-aziA6 E. coli expression vector for AziA6, Km
r
 This study 
pET-24a-aziG E. coli expression vector for AziG, Km
r
 This study 
pET-aziG-H44A E. coli expression vector for AziG H44A, Km
r
 This study 
pET-aziG-H48A E. coli expression vector for AziG H48A, Km
r
 This study 
pET-aziG-E57A E. coli expression vector for AziG E57A, Km
r
 This study 
pET-aziG-S58A E. coli expression vector for AziG S58A, Km
r
 This study 
pET-aziG-S61A E. coli expression vector for AziG S61A, Km
r
 This study 
pET-24a-aziB E. coli expression vector for AziB, Km
r
 This study 
 73 
 
CHAPTER III 
 
AZINOMYCINS: EVALUATION OF BIOLOGICAL ACTIVITY OF CRYPTIC 
PRODUCT FROM ∆AZIA2 STREPTOMYCES SAHACHIROI* 
 
INTRODUCTION 
 
Azinomycins are antitumor natural products produced by Streptomyces 
sahachiroi.
81-84
 As detailed in chapter I, the structural, feeding, and bioinformatic studies 
have suggested that the compounds are produced by a combination of a polyketide 
synthase (PKS) and non-ribosomal peptide synthetases (NRPSs).
103-108
 Chapter II 
discusses the formation of the naphthoate moiety 5-methyl-1-naphthoic acid through the 
combined efforts of PKS AziB and thioesterase (TE) AziG. This naphthoic acid 
eventually obtains a methoxy substituent at the 3’ position, a fragment installed by 
AziB1 and AziB2.
134
 The resulting naphthoic acid, 3-methoxy-5-methyl-1-naphthoic 
acid, forms an ester bond with the epoxide moiety catalyzed by NRPSs. Previous studies 
have suggested that there are four substrates for the NRPSs while there are five modules 
in the gene cluster. It has been proposed that 3-methoxy-5-methyl-1-naphthoic acid and 
3-methyl-2-oxo-but-3-enoic acid, which eventually forms an epoxide, are substrates of 
AziA1 and AziA3 respectively.
107, 108
 Thus, there are additional condensation (C) and 
peptide carrier protein (PCP) domains located on AziA2 between AziA1 and AziA3 
(Figure 29). The existence of AziA2 is one of the mysteries in the biosynthesis of 
azinomycins because condensation between these two substrates seems a simple reaction 
which occurs between the carbonyl carbon of the naphthoic acid and α-hydroxyl oxygen 
reduced from α-ketone by keto-reductase (KR) domain on AziA3. It is not clear why the 
*Part of the data reported in this chapter is reprinted from “Activation of cryptic 
metabolite production through gene disruption: Dimethyl furan-2,4-dicarboxylate 
produced by Streptomyces sahachiroi” by Simkhada, D.; Zhang, H.; Mori, S.; and 
Watanabe C. M. H., 2013. Beilstein J. Org. Chem., 9, 1768-1773, Copyright [2013] by 
the authors, Licensed by Beilstein-Institut.  
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naphthoic acid has to be transferred onto another PCP domain prior to the condensation 
reaction, which is seemingly an inefficient catalytic mechanism.  
 
 
 
 
Figure 29. Azinomycin NRPS modules and their substrates 
 
 
 
PRELIMINARY RESEARCH 
 
The significance of AziA2 in azinomycin production was assessed by a 
functional knockout of aziA2 in S. sahachiroi.
109
 It was carried out by replacement of the 
middle portion of aziA2 with a thiostrepton resistance gene (tsr) in the organism’s 
genomic DNA. This was accomplished by double crossover with the shuttle vector pKC-
AziA2, which was created from pKC1139 containing the apramycin resistance marker. 
The mutants were selected by thiostrepton and apramycin for single crossover, and the 
double crossover mutants were subsequently generated by selection by thiostrepton. The 
aziA2 disruption mutant was confirmed by PCR and southern hybridization. Comparing 
the Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) profile of 
the organic extract of S. sahachiroi wild type and the ∆aziA2 mutant clearly showed that 
there was no production of azinomycins in the mutant. This indicated that AziA2 is an 
essential protein to produce azinomycins. Analysis of the mutant by RP-HPLC showed 
that the disruption of aziA2 enhanced production of a non-azinomycin related natural 
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product which was eventually identified as dimethyl furan-2,4-dicarboxylate 55 (Figure 
30).  
 
 
 
 
Figure 30. HPLC analysis of WT and ∆aziA2 mutant 
RP-HPLC profile of S. sahachiroi crude organic extract of WT (a) and of ∆aziA2 (b). 1: 
dimethyl furan-2,4-dicarboxylate (55), 2: 3-methoxy-5-methyl-1-naphthoic acid (4), 3: 
azinomycin A (1), 4: azinomycin B (2). The chemical structure of dimethyl furan-2,4-
dicarboxylate is shown on right. 
 
 
 
The overproduction of dimethyl furan-2,4-dicarboxylate in the disruption mutant 
could be explained by the fact that regulation of genes in microorganisms is highly 
dependent on the external or internal environment.
135
 Gene clusters in the genome are 
activated depending on specific factors to which the microorganisms are exposed while 
(55) 
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other gene clusters remain silent until they are demanded. In the ∆aziA2 S. sahachiroi 
mutant, genes which produced dimethyl furan-2,4-dicarboxylate were activated. A new 
question arose from this observation: whether the compound was produced as a 
replacement of the cytotoxic azinomycins or for other beneficial purposes. 
 
RESULTS AND DISCUSSION 
 
Cytotoxicity and Chemotaxis Assays against Jurkat Cells 
 Organic extract of aziA2 disruption mutant and its purified major product, 
dimethyl furan-2,4-dicarboxylate, were assessed against Jurkat cells, a human T 
lymphocyte cell line, for cytotoxicity and inhibition of chemotaxis. Cytotoxicity assays 
were performed by incubation with the samples for 24 h. Chemotaxis assays were 
performed utilizing Boyden chambers.
136
 FTY720 (fingolimod), a derivative of the 
natural product myriocin produced by Iscaria sinclarli, was used as a control. It is 
known as an immunomodulating drug that inhibits lymphocyte migration from lymphoid 
organs.
137
 
A Boyden chamber has two wells separated by a membrane which can be 
penetrated by certain cancer cells but keeps chemical substances from mixing between 
wells. In the chemotaxis assay, cells are added into the top well with fresh culture 
medium; a nutrient source (chemotactic agent) and a test substance are added to the 
bottom well. Following incubation, the bottom well is observed for cells. Cells will be 
present if the test substance does not inhibit the chemotactic activity, but cells remain in 
the top well if the test substance is active. The number of live cells in each well was 
counted by green fluorescent (GR) dye staining of the nuclei followed by fluorescent 
detection.  
Compared to the wild type extract which contains azinomycins as antitumor 
agents, it was shown that both the crude extract of the aziA2 disruption mutant and 
purified dimethyl furan-2,4-dicarboxylate have neither cytotoxicity nor inhibit the 
chemotactic activity of Jurkat cells (Figure 31 and Appendix Figure 80). This 
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observation showed no antitumor activities of dimethyl furan-2,4-dicarboxylate and also 
suggested that S. sahachiroi does not produce organic extractable antitumor secondary 
metabolites other than azinomycins. 
 
 
 
 
Figure 31. Cytotoxicity and chemotaxis assay against Jurkat cells 
The number of cells is the relative numbers to the control (green) which is assumed 100. 
Cytotoxicity assay: Cy C1: control without FBS in the culture medium, Cy C2: control 
without any samples, Cy C3: control with FTY720 (1.0 µg/mL), Cy C4: control with 
FTY720 (0.75 µg/mL), Cy C7: control with 1 µL of stock solution (methanol/ethyl 
acetate/t-butyl methyl ether = 60/30/10), Cy ∆A2: aziA2 disruption mutant extract, Cy 
WT: wild type extract, Cy DL: 1 µg/mL of dimethyl furan-2,4-dicarboxylate, Cy DM: 
10 µg/mL, Cy DH: 25 µg/mL. Chemotaxis assay: Ch C1: control without FBS in the 
bottom well, Ch C2: control without any samples, Ch C3: control with FTY720 (1.0 
µg/mL), Ch C4: control with FTY720 (0.75 µg/mL), Ch C7: control with 1 µL of stock 
solution, Ch ∆A2: aziA2 disruption mutant extract, Ch WT: wild type extract, Ch DL: 1 
µg/mL of dimethyl furan-2,4-dicarboxylate, Ch DM: 10 µg/mL, Ch DH: 25 µg/mL. 
 
 
 
Anti-Bacterial and Anti-Fungal Assays 
 Dimethyl furan-2,4-dicarboxylate was also assayed against two bacteria, the 
gram-negative Escherichia coli and the gram-positive Bacillus subtilis for anti-bacterial 
activity which azinomycins have been shown to have, and against the fungus, 
Saccharomyces cerevisiae, for anti-fungal activity (Figure 32).
81, 82
 It was shown that 
dimethyl furan-2,4-dicarboxylate did not inhibit growth of these microorganisms, which 
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suggested that the aziA2 disruption mutant no longer has its natural defense system 
against these invaders. This might explain why S. sahachiroi has achieved and continued 
to maintain the production of such complex natural products which require many energy 
consuming genes and proteins for their biosynthesis. Production of azinomycins seems 
to be an important survival strategy for the bacterium. It also could be postulated that it 
was not necessary for S. sahachiroi to activate other gene clusters and overproduce 
alternative weapons for survival because of the sterilized medium environments where 
there were no other inhabitants. In other words, dimethyl furan-2,4-dicarboxylate could 
be overproduced for other beneficial purposes. 
 
 
 
 
Figure 32. Antibacterial and antifungal assays 
 
 
 
Neurite Outgrowth Assay 
 To evaluate other properties of the natural product purified from the aziA2 
disruption mutant organic extract, dimethyl furan-2,4-dicarboxylate, neurite outgrowth 
assay was performed on PC-12 cells. The PC-12 cell line which was derived from the rat 
neuroendocrine tumor, pheochromocytoma, stops dividing and starts differentiating into 
neuron like cells several days after exposure to an appropriate neural growth factor.
138, 
139
 This was observed in the control assay where all-trans-retinoic acid was used as the 
growth factor.
140, 141
 PC-12 cells incubated with dimethyl furan-2,4-dicarboxylate, 
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however, continued growing in number (Figure 33). This observation showed that the 
novel natural product does not possess activity as a neurite outgrowth factor.  
 
 
 
 
Figure 33. Neurite outgrowth assay 
PC-12 cells were incubated with 1, 5, 10, or 50 µg/mL of dimethyl furan-2,4-
dicarboxylate for 6 days. All-trans-retinoic acid (1 µg/mL) was used as the control of 
neuronal differentiation. Retinoic acid made PC-12 cells stop dividing and start 
differentiating.  
 
 
 
SIGNIFICANCE 
 
 It has been shown that dimethyl furan-2,4-dicarboxylate, which is overproduced 
by the aziA2 disruption mutant of S. sahachiroi, does not share antitumor or antibacterial 
activity with the azinomycins. The molecule neither displays antifungal activity nor 
enhances neurite outgrowth of PC-12 cells. The compound may be generated as a 
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replacement for azinomycins, but it is not biologically active or has a narrow spectrum 
of activity. This may be the beginning of evolution process, in which the bacterium starts 
synthesizing a new secondary metabolite which could or could not be bioactive. It is also 
possible that dimethyl furan-2,4-dicarboxylate was not produced as a replacement for 
azinomycins, but was produced for other purposes. This may be caused by lack of 
azinomycin production or aziA2 dysfunction, which could cause an internal 
environmental change of S. sahachiroi comparing to the wild type. Production of 
antibiotics is not essential for the organism in a research lab because there are no 
competitors in the sterilized culture medium. The compound was possibly produced for 
other biosynthetic pathways which might be limited by lack of energy consumed by 
azinomycin production in the wild type S. sahachiroi. Therefore, it is possible that 
∆aziA2 S. sahachiroi activates a gene cluster to synthesize a novel natural product if the 
disruptant is exposed to the external stimulus including the existence of competitors or 
other stress factors.  
 The other interesting topic of AziA2 is the mystery of its unusual architecture, 
which will be evaluated in the future. AziA2 has sequential domains of C-PCP-C 
domains whose first C domain is thought to catalyze a transfer of 3-methoxy-5-methyl-
1-naphthoic acid to the PCP domain from another PCP domain of AziA1 (A-PCP 
module), and the second C domain is thought to catalyze a condensation between the 
naphthoic acid and a substrate of AziA3 (A-KR-PCP module), putatively 3-methyl-2-
oxo-but-3-enoic acid. Why does this unique protein contain extra C and PCP domains 
for the condensation between the substrates? The direct analysis of the protein is difficult 
because it is a module which does not perform a catalytic reaction alone and is a part of 
the NRPS/PKS hybrid containing four other modules. It is essential to examine the 
overall function of AziA2 in the presence of substrate bound AziA1 and AziA3. The 
necessity and function of the extra C-PCP domains could be assessed by various 
experiments including mutation and disruption studies on these domains to evaluate if a 
mutant lacking these domains is still able to catalyze the condensation reaction. 
Overexpression of only these domains could be useful in examining the transfer of the 
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naphthoic acid. Understanding of the function of AziA2 would shed new light on the 
activity and function of this NRPS/PKS hybrid.  
 
MATERIALS AND METHODS 
 
Chemicals and General Procedures 
 Jurkat clone E6-1, PC-12, culture medium RPMI 1640, fetal bovine serum 
(FBS), and antibiotic penicillin-streptomycin solution (x100) were purchased from 
American Type Culture Collection (ATCC, Manassas, VA, USA). Heat-inactivated 
horse serum (HHS) was purchased from Life Technologies (Termo Fisher Scientific, 
Waltham, MA, USA). Frozen stock of Jurkat cells was cultivated in a sterilized Petri 
dish with 15 mL RPMI with 10 % FBS and 150 µL antibiotic solution at 37 oC in 5 % 
CO2 for 3-4 days. Before the culture medium turned yellow, 5 mL of the medium was 
transferred into 75 cm
2
 culture flasks where 25 mL of fresh RPMI medium with FBS and 
250 µL of antibiotic solution were added. This step was repeated every 3-4 days to keep 
the cells from being overgrown and unhealthy. PC-12 cells were cultivated in the same 
manner except for the following. Collagen coated dishes (Collagen Type IV, BioCoat, 
Becton Dickinson, Franklin Lakes, NJ, USA) were used culturing. The medium 
contained 5 % FBS and 10 % HHS but did not contain antibiotic.  
 
Cytotoxicity Assay against Jurkat Cells, Human Cell Line of T Lymphocyte 
 Jurkat cells were cultivated in the cell culture medium (RPMI 1640 with 10% 
fetal bovine serum) and maintained in 75 cm
2
 culture flasks at 37 
o
C in 5% CO2. Cells 
were harvested by centrifugation (10 min at 1000 rpm), washed twice with the fresh 
culture medium without serum, and resuspended in the fresh culture medium. The 
number of cells was counted by hemocytometer, and the medium volume was adjusted 
to give 2,000,000 cells/mL. 100 µL of cells (200,000 cells) was added to 600 µL of cell 
culture medium in 24-well plates which contained either dimethyl furan-2,4-
dicarboxylate or aziA2 disruption mutant and wild type extracts at a final concentration 
 82 
 
of 1, 10, or 25 µg/mL. Cells were incubated for 24 hours and transferred to 1.5 mL 
eppendorf tubes to centrifuge for 15 min at 14,000 rpm. The medium was removed, and 
cells were washed with phosphate buffered saline (PBS) without manganese and calcium 
ions. Cells were lysed and stained by CyQUANT® Cell Proliferation Assay Kit 
(invitrogen), and subsequently placed in a black 96-well plate and analyzed using a Bio-
Tek fluorometer to measure relative fluorescence. 
 
Chemotaxis Assay against Jurkat Cells, Human Cell Line of T Lymphocyte 
 Cells were harvested and counted as detailed above. Transwell®, 24 well plates 
with permeable supports (5.0 µm polycarbonate membrane, Boyden chamber, Costar) 
were used. The bottom well contained 600 µL of cell culture medium with 1 µg/mL, 10 
µg/mL, or 25 µg/mL of either dimethyl furan-2,4-dicarboxylate or 25 µg/mL of aziA2 
disruption mutant and wild type extracts. 100 µL of cells (200,000 cells) was added to 
the top well. After incubation for 24 hours, cells were collected from the bottom well to 
assess how many cells migrated. Cells were collected and analyzed by the same method 
as detailed for the cytotoxicity assay. 
 
Anti-Bacterial and Anti-Fungal Assays 
 Escherichia coli (DH10b) was cultivated in 5 mL of LB medium at 37 
o
C 
overnight. Cells were diluted with the fresh medium to give OD600 = 0.1. 100 µL of 
diluted cells was added to 96-well plates containing the final concentrations of 0, 1, 5, 
25, 50 µg/mL of dimethyl furan-2,4-dicarboxylate. Following incubation at 37 
o
C for 24 
hours, the cell density was measured with a Bio-Tek microplate reader. For Bacillus 
subtilis, nutrient broth (Difco, Becton Dickinson) was used as the culture medium, and 
for Saccharomyces cerevisiae, cells were cultured in YPG medium (yeast extract, 10 g; 
peptone, 20 g; galactose, 20 g for 1 L) at 30 
o
C. The final concentrations of the 
compound for these two were 0, 1, 10, 50, 100 µg/mL. 
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Neurite Outgrowth Assay 
 PC-12 neuronal cells were cultivated in 100 mm Collagen Type IV dishes at 37 
o
C in 5% CO2 with RPMI 1640, supplemented with 10% HHS and 5% FBS. The cells 
were collected from the culture dish by flushing with the serum free medium and 
transferred to a 15 mL falcon tube. The cells were centrifuged for 15 min at 1000 rpm, 
washed twice with the serum free medium, and resuspended in RPMI 1640 with a trace 
amount of serum (0.5 % heat-inactivated horse serum and 0.25 % fetal bovine serum) to 
give 50,000 cells/mL. The cells (200 µL) were transferred to a 96-well Collage Type IV 
plate (10,000 cells/well). Following 24 h incubation for to allow the cells to adhere to the 
plate, dimethyl furan-2,4-dicarboxylate was added to give final concentrations of 1, 5, 
10, and 50 µg/mL. Each well was visually monitored over 1 week for neurite outgrowth 
and intercellular connections. 
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CHAPTER IV 
 
DISCOVERY AND EVALUATION OF MACRO-LACTONE ANTI-
METASTATIC MARINE NATURAL PRODUCT, NUIAPOLIDE* 
 
INTRODUCTION 
 
Natural product extracts have been used as crude drugs for thousands of years in 
locations all over the world, such as Mesopotamia, Egypt, India, and China.
17-20
 They 
have been used in combinations of diverse natural products produced by one or more 
organisms for treating various diseases and symptoms including pain, inflammation, and 
infection. The history of herbal drug use clearly shows the significance of natural 
products as medicines. The techniques utilized to prepare and develop these therapies 
have occasionally misled physicians, sometimes leading to treatment of patients with 
unbeneficial or even toxic substances. This was especially common before robust 
statistical analysis methods had been developed. The natural product industry entered 
into a new era after the discovery of penicillin in 1928, which was the first pure 
antibiotic isolated from the fungus Penicillium rubens.
12, 29
 Although it took more than 
ten years for penicillin to be clinically applied, the remarkable success led researchers to 
the large-scale exploration of other microorganisms in all kind of environments on earth. 
This has provided a great diversity of compounds with high selectivity and specificity of 
action. This is difficult to reproduce when studying synthetic compounds. In the period 
of 01/1981-12/2010, natural product relating compounds occupy 50.3 % of all the new 
approved drugs.
1
 The search for bioactive natural products has been hastened by the 
development of high throughput screening (HTS) methods in early 1990s, which 
*Majority of the data reported in this chapter is reprinted from “Macrolactone 
Nuiapolide, Isolated from a Hawaiian Marine Cyanobacterium, Exhibits Anti-
Chemotactic Activity” by Mori, S.; Williams, H.; Cagle, D.; Karanovich, K.; Horgen, F. 
D.; Smith, R., III; Watanabe, C. M. H., 2015. Mar. Drugs, 13, 6274-6290, Copyright 
[2015] by the authors, Licensed by MDPI, Basel, Switzerland. 
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currently can assess more than 250,000 samples per day.
142
  
The most important source of natural products is Streptomyces consisting of 
more than 500 species and thousands of strains, which makes it the largest genus of 
Actinobacteria.
143
 Streptomyces species have large genomes for bacteria, containing 
substantial numbers of genes involved in the production of secondary metabolites. This 
allows the species to produce more than two-thirds of all known antibiotics of natural 
origin, including streptomycin, chloramphenicol, tetracycline, etc.
144
 Another aspect 
making the bacteria popular is their relative ease to collection and cultivation. The 
species is predominantly found in soil which is easy to access and study in a regular 
biological laboratory. It has been hypothesized that environments that people cannot 
easily investigate possess a much greater source of natural products.
145
 The ocean covers 
more than 70% of the earth’s surface. The microbial population in seawater samples was 
examined based on the data collected by Sorcerer II Global Ocean Sampling (GOS), and 
it was estimated that there were more than 6,000,000 proteins available. This is nearly 
twice the number of proteins existing in the previous database, and some of them had no 
similarities to known proteins.
146
 The data supports the idea that there is a high diversity 
of natural products in ocean microbial communities.  
Halichondrin B is a recent example of a successful marine natural product. It was 
isolated from a marine sponge Halichondria okadai and found to have anticancer 
activity in 1986.
147
 Through the synthetic study of the compound, it was revealed that 
the simplified analog of the natural product, named eribulin, possessed the same level of 
activity as the parent compound.
148, 149
 Eribulin was eventually approved by the Food 
and Drug Administration (FDA) in 2010, by the European Medicines Agency (EMA) in 
2011, and subsequently by other countries.
150, 151
 Other marine natural products and/or 
their derivatives have also been marketed such as ziconotide (Prialt®, Elan 
Pharmaceuticals) from a tropical cone snail for the treatment of pain, cytarabine 
(Cystosar-U, Teva Pharmaceuticals) and ecteinascidin 743 (Yondelis®, Pharma Mar 
S.A.) for the treatment of cancer, and omega-2-acid ethyl esters (Lovza®, 
GlaxoSmithKline) for the treatment of hypertriglyceridemia. 
152-154
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Natural products are investigated as therapies for various types of disease, 
including cancer which is the greatest cause of human death in many developed 
countries.
40-43
 Cancers appear when living cells fail to destroy themselves by apoptosis 
after mutations in certain directions caused by genetics, life styles, exposure to 
carcinogens, or their combination.
155
 Because all adult cells have the potential to become 
cancer cells, there are countless types of cancer. This creates a substantial hurdle for 
cancer treatment. There are two additional barriers which make treatment complicated. 
One is the fact that human immunity, which people naturally possess, rarely destroys 
cancer cells once they start growing because they arose from normal cells which are not 
attacked by immune cells.
156
 Therefore, cancer cells do not stop growing until they 
finally kill the patient. The other major problem of cancer is metastasis, a phenomenon 
of the cancer spread from one location to another through the circulatory system of the 
body, such as cardiovascular and lymphatic systems.
157
 Because many cancers are not 
visible and do not cause symptoms until they grow sufficiently large, they may hide in 
other parts of the body for months or years even though cancer at the original site is well 
treated. This ultimately tends to be the source of death for the patients. Therefore, 
preventing metastasis is equally important to annihilating cancer cells. 
Cancer metastasis is enhanced by chemotaxis, the migration of a cell by response 
to a chemical stimulus.
158
 Chemotaxis is seen in almost all organisms, including single-
cell and multicellular organisms. Single-cell organisms, such as bacteria, approach 
nutritional chemicals but flee from toxic chemicals.
159
 Multicellular organisms utilize the 
phenomenon for single cell functions, such as the movement of sperm toward an egg or 
of immune cells toward their targets.
160, 161
 The process, however, also inevitably enables 
some cancer cells to migrate from one location to another, triggering the development of 
cancers at the new site. Because many cancers are not visible and do not present 
symptoms until they grow sufficiently large, they may hide in other parts of the body for 
months or years even though the original cancer has been eliminated.  Therefore, finding 
a chemical which blocks the chemotactic activity of cancer cells adds a new strategy 
toward cancer treatment as an anti-metastatic agent.
162
 The chemical is also desired to 
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have no cytotoxicity because cytotoxic chemicals to cancer cells tend to be cytotoxic to 
the normal cells leading to adverse reactions. 
 
RESULTS AND DISCUSSION 
 
Evaluation of Hawaiian Marine Natural Product Extracts for Anti-Chemotactic 
Behavior 
To identify putative immunosuppressive or anti-metastatic agents from natural 
products, microorganisms in Hawaiian ocean were assessed in several steps. A total of 
560 crude extract samples, which include various organisms and various extraction 
methods, were evaluated for their ability to inhibit the chemotactic activity of Jurkat 
cells.
136
 Jurkat is an immortalized line of human T lymphocyte cells that are capable of 
exhibiting migration toward a nutrient source, fetal bovine serum (FBS).
163
 Boyden 
chambers were used to assess the activity of the extracts because Jurkat cells are 
suspension cells.
136
 FTY720, a derivative of the natural product myriocin and an 
approved drug for the treatment of multiple sclerosis (MS), was utilized as a control 
substance.
137
 
 The crude extract samples were assayed at 25.0 µg/mL which is considered as 
micro-molar concentration scale for a majority of natural products. The result was 
visually observed with an inverted microscope (Figure 34). It was clearly shown that 
there was cell migration when the chemotactic agent fetal bovine serum (FBS) was 
present (Figure 34-b comparing to Figure 34-a), but the cells did not approach the high 
concentrated nutrient location when an active compound was present (Figure 34-c and 
Figure 34-d). However, the dead cells were observed in the presence of FTY720 which 
is known as a cytotoxic agent, but the cells were alive with the CL13-F10 sample. 50 
samples including CL13-F10 were found to inhibit the chemotactic activity of Jurkat 
cells, which were subjects to assess for cytotoxicity.  
 
 88 
 
 
Figure 34. Evaluation of Jurkat cultures in the Boyden chamber assay 
Microscopic images of the bottom well of Boyden chambers after 24 h incubation; (a): – 
FBS  and – chemotactic agent, (b): + FBS and – chemotactic agent, (c): + FBS and + 
FTY720, (d): + FBS and + CL13-F10. Shrinkage of cells in (c) is indicative of cell 
death. 
 
 
 
Cytotoxicity Assay for Active Crude Extracts 
 An ideal natural product with anti-metastatic potential would be one which 
inhibits the chemotactic activity but does not have cytotoxicity because most chemicals 
which are cytotoxic to cancer cells are also cytotoxic to healthy cells. 50 samples 
capable of inhibiting Jurkat cell chemotaxis were assessed for their cytotoxicity. The 
relative number of live cells was counted by fluorescent emission followed by green 
fluorescent (GR) dye staining, and it was compared to the relative number of live cells in 
the control sample which did not contain the test substances. It was shown that 7 out of 
50 samples did not demonstrate cytotoxicity against Jurkat cells at the concentration of 
25.0 µg/mL (Figure 35). 
 
 
 
-FBS control +FBS control +FBS, +FTY720      
control 
+FBS,  
+CL13-F10 
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Figure 35. Cytotoxicity profile analysis of extracts 
The turquoise bar represents samples where the percentage of live cells is > 90 % of the 
control. The black bar represents samples where the percentage of live cells is < 90 %.  
Controls included wells grown without FBS (-FBS) and with FTY720 (5 µg/mL).  
Sample codes are library plate number and coordinate on the plate. 
 
 
 
Evaluation of Fractionated Extracts for Anti-Chemotactic Behavior 
The sample CL013-F10 (SM 1-12-16), which was the water and solid phase 
extract of the Cyanobacterium 071905-NII-01, was chosen for further evaluation 
because it had better chemotaxis inhibition activity at lower dosage, and it did not kill 
cells at these concentrations (10 µg/mL) (Appendix Figure 81). The active samples, 
which were extracted with dichloromethane (FR022) or methanol (FR023), were 
fractionated (1 min/fraction) into 24 wells in a 96-well plate for further chemotaxis 
assays. Each fraction from both extracts was examined for anti-chemotactic activity of 
Jurkat cells. Each extract provided three active fractions. The retention times of the 
active fractions for each extract were different from one another. The active fractions 
from FR022 were A3 (4-5 min), A11 (12-13 min), and A12 (13-14 min) (Figure 36-a), 
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and the active fractions from FR023 were A8 (9-10 min), B2 (15-16 min), and B3 (16-17 
min) (Figure 36-b).  
 
 
 
 
Figure 36. Fragmentation of CL013-F10 (Dr. David Horgen) and chemotaxis assays 
The samples were extracted with (a) dichloromethane (FR022) and (b) methanol 
(FR023), and each fraction was assessed for inhibition Jurkat chemotactic activity. The 
yellow bars in the LC profile are the active fractions. Yellow to orange colors in the 
table represents the level of activity. 
(a) 
(b) 
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The LC profiles and activity patterns of FR022 and FR023 showed similar 
patterns except the retention times of the active components were shifted reflecting the 
different gradients of the separation.  This suggested the same active components were 
present in both samples with FR022 fractions A3 and A11/A12 corresponding to FR023 
fractions A8 and B2/B3, respectively and likewise, activity at A11 and A12 from FR022 
(corresponding to B2 and B3 from FR023). This was confirmed by photodiode array 
(PDA) map and LC-MS (Appendix Figure 82-Appendix Figure 86). Fractioins FR022-
A3/FR023-A8 showed a major component with a mass of 788.6±0.2 Da (m/z 789.6, 
compound 56). These two natural products, which had molecular masses of 788.6±0.2 
Da (compound 56) and 982.7±0.2 Da (NP982), respectively, were subjected to 
purification by LC-MS. Compound 56 was isolated to purity, its anti-chemotactic 
activity confirmed and was obtained in sufficient quantities for further analysis 
(Appendix Figure 87).  Nuiapolide (56) showed chemotactic activity at concentrations as 
low as 1 g/mL (1.3 M) (Figure 37 and Appendix Figure 87).  Isomeric components of 
NP982 and low isolated yields precluded further analysis. 
 
 
 
 
 
 
Figure 37. Evaluation of nuiapolide (56) activity at 1 µg/mL 
Images of microscope fields of the bottom well after 24 h of incubation; (a): bottom well 
received no FBS and no test substance, (b): bottom well received 10 % FBS and no test 
substance, (c): bottom well received 10 % FBS and FTY720 (5 µg/mL), (d): bottom well 
received 10 % FBS and Nuiapolide (56) (1 µg/mL). 
 
 
 
 
(a) –FBS control (b) +FBS control (c) +FBS +FTY720  
      control 
(d) +FBS  
      +Nuiapolide (56)   
      (1 µg/mL) 
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Cell Cycle Analysis of Nuiapolide (56) 
 The effect of Nuiapolide (56) to Jurkat cell cycle was analyzed by flow 
cytometry. The population ratio in the cell cycle phases of the living cells was calculated 
from the histogram of flow cytometry, which distinguishes the state of cells into three 
distinct phases; Gap 0 (G0) or Gap 1 (G1), Synthesis (S), and Gap 2 (G2) or Mitosis (M) 
phases.
164, 165
 The cell cycle is divided into four phases and one resting phase, G0 in 
which cells leave the cycle and stop dividing. In the interphase state where cells continue 
growing the size and synthesizing a new copy of DNA, there are three phases, G1, S, 
and G2. G1 phase is the growth or Gap 1 phase and represents the first of the four phases 
of the cell cycle. The G1/S phase transition is a major checkpoint in the cell cycle, with 
S-phase representing the point in the cell cycle when DNA replication occurs. G2 phase 
is a period of rapid cell growth and protein synthesis as the cell prepares itself for cell 
division. The G2/M phase transition is another major checkpoint in the cell cycle, with 
M phase representing the final phase of the cell cycle; the cell’s nucleus is separated into 
two identical sets of chromosomes and cytokinesis occurs, i.e. the cell divides into two 
daughter cells.   
The Jurkat cells were incubated with nuiapolide (56) for up to 6 h. The flow 
cytometry analysis showed the significant decrease of ratio of G0/G1 phase in all the 
incubation times in comparison to the control (0 h). S phase decreased but G2/M phase 
increased over time, which displayed that the cells could progress into S and following 
G2/M phase but arrested at the last stage. It suggested that nuiapolide (56) allows cells to 
synthesize new DNAs, but it inhibits the efficient cell division (Figure 38 and Appendix 
Figure 88). We did not observe any 8N cells; the cell cycle is perturbed where there is a 
slowing or block in G2/M. 
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Figure 38. Cell cycle analysis of nuiapolide (56) treated Jurkat cells 
The Jurkat cells were analyzed by flow cytometry after 2, 4, and 6 h incubation with 
nuiapolide (56). It was shown that change of the ratio of G0/G1, S, and G2/M phases 
over the time course including the control which was prior to nuiapolide (56) treatment 
was shown in a histogram (a) and on a table (b). In the histogram, the peak around at 
200 nm absorption, a gap between two peaks, and the peak around at 400 nm absorption 
represent G0/G1, S, and G2/M phases respectively. 
 
 
 
Structural Analysis of Nuiapolide (56) 
The molecular formula of nuiapolide (56) was established as C44H84O11 based on 
HRMS (m/z [M+H]
+
 789.6076, calcd for C44H85O11, 789.6092; [M+Na]
+
 811.5895, 
calcd for C44H84O11Na, 811.5911) and requires three degrees of unsaturation. The 
structure was elucidated by 
1
H NMR, 
13
C NMR, 
13
C NMR DEPT, COSY, TOCSY, 
HSQC, HSQC-TOCSY, in methanol-d4 and DMSO-d6 (Figure 40-Figure 55 and Table 
3). 
13
C NMR showed 15 distinct signals, some of which (δC 20.8-21.5, 36.2-37.4, and 
69.8-70.8) were overlapped with multiple peaks.  HSQC correlation paired the 
1
H and 
13
C NMR signals. C-40 at δC 33.91, C-1 at δC 166.90, and C-3 at δC 161.20, which were 
absent in the HSQC correlation and DEPT, were predicted as R4C for C-40 and a 
substituted alkene or carbonyl carbon for C-1 and C-3. In HMBC, C-40 correlated with 
H-41-43 (δH 0.93) and H-39 (δH 5.02).  As nine protons were predicted to be at H-41-43, 
C-40 and C-41-43 are due to a tert-butyl group attached to C-39. Based on the chemical 
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shift and HMBC correlation between H-39 and C-1, C-39 and C-1 were assigned as an 
α-carbon on an oxygen linkage and carbonyl carbon respectively, indicating that the 
molecule is an ester. C-1 had an HMBC correlation with alkene proton H-2. H-2 
correlated with C-3, which also exhibited correlations with H-4 and H-44. Since H-44 
consisted of 3 protons, this gives methyl substitution on the alkene C-3 on which C-4 
extends the carbon chain further. No additional unsaturated carbons or substitutions were 
found except for hydroxyl groups present in the molecule, thus confirming that 
nuiapolide (56) is a macrolactone with an alkene and two side chains locating near the 
ester functional group (Figure 39) and nine hydroxyl groups distributed throughout the 
saturated hydrocarbon ring structure. 
 
 
 
 
Figure 39. Partial structure of nuiapolide (56) with key HMBC correlations 
 
 
 
Since three distinct signals of protons on hydroxyl carbons were found in the 
1
H 
NMR, this signified three different environments for these hydroxyl groups.  These 
protons (locations) were indicated as H-a, H-b, and H-c at δH 3.78, 3.57, and 3.42, 
respectively. H-a contains two protons which had TOCSY correlations with H-4 and H-
b, but they neither had nor shared COSY correlation. This suggested that there were at 
least two carbons between H-a and others.  In HSQC-TOCSY, in addition to correlations 
with carbons at δC 36.2-37.4, there was a correlation with C-8 (δC 43.51), which was 
proposed as the carbon between each H-a. H-c consists of one proton correlated with H-
39 and H-b in TOCSY but not in COSY. H-c and H-39, however, shared a correlation in 
COSY. These indicated that there is one carbon between H-c and H-39 and at least two 
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carbons between H-c and H-b. Six protons in H-b were almost identical, thus their 
positions were likely equally distributed and spread enough not to affect each other. Two 
distinct HSQC-TOCSY correlations with δC 36.2-37.4 and 20.8-21.5 indicated there 
were two isolated environments between each H-b. This confirmed that the hydroxyl 
groups at H-b appear at every four carbons.  Because of the ring size, there cannot be 
more than four carbons between H-b and H-a or H-c, indicating there are three carbons 
between these.  
The proposed location of hydroxyl groups was confirmed by the number of 
carbons in environments through the ring structure (Appendix Figure 89). Nine hydroxyl 
carbons were found at δC 67.58 (C-37) and δC 69.8-70.8 (C-7, C-9, C-13, C-17, C-21, C-
25, C-29, and C-33). There were 16 α-carbons of hydroxyl groups (except for C-8) at δC 
37.55 (C-38) and 36.2-37.4 (C-6, C-10, C-12, C-14, C-16, C-18, C-20, C-22, C-24, C-
26, C-28, C-30, C-32, C-34, and C-36). Seven β-carbons (except for C-5) were located at 
δC 20.8-21.5 (C-11, C-15, C-19, C-23, C-27, C-31, and C-35). The location of hydroxyl 
groups was further confirmed by 
1
H NMR, 
13
C NMR, COSY, TOCSY, and HMBC in 
DMSO-d6 which showed signals of hydroxyl protons (Table 3 and Figure 50-Figure 55). 
The new peaks appeared at δH 4.14, 4.15, 4.44, and 4.47. COSY correlations showed 
that the peaks at δH 4.44 and 4.47 were from hydroxyl groups at position H-a, the peak at 
δH 4.14 was from H-b hydroxyl groups, and the peak at δH 4.15 was from position H-c, 
which was confirmed by a TOCSY correlation with H-39. HMBC showed correlations 
between δH 4.44/4.47 and C-8, between δH 4.14 and δC 36.2-37.4/69.8-70.8, and 
between δH 4.15 and C-38. Based on the above analyses, the structure of nuiapolide (56) 
was determined, as shown in Figure 40. 
The structure suggested that the compound belongs to the polyketide class of 
natural products and displays structural similarity to the caylobolides, which were shown 
to be cytotoxic against some cancer cell lines.
166, 167
 Nuiapolide (56) and caylobolides A 
(57) and B (58) share the core structure of a macro-lactone. They contain a large 
saturated carbohydrate ring with several hydroxyl groups and similar side chains around 
the ester functional group. The number of carbons in the ring structure, however, was 
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slightly greater in compound 56 (39 carbons) than in caylobolides (35 carbons). Given 
the structure of 56 and its Hawaiian origins, we named it nuiapolide (56).  Nuiapo means 
big circle in Hawaiian and “ide” indicates the macrolide.  
 
 
 
 
Positiona 
δH (J in Hz) 
in MeOH-d4 
δH (J in Hz) 
in DMSO-d6 
δC in MeOH-
d4, type 
δC in DMSO-
d6, type 
TOCSY 
HSQC-
TOCSYb 
HMBCc 
1 - - 166.90, C 166.04, C - - - 
        
2 5.74, s 5.67, s 115.73, CH 116.69, CH 4, 44, 41-43 44 1, 3, 4, 44 
        
3 - - 161.20, C 160.04, C - - - 
        
4 
2.58, m and 
2.83, m 
2.59, m 32.69, CH2 33.11, CH2 
2, Ha, 5, 6, 
HCf 
5 2, 3, 5 
        
5 1.60, m 1.49, m 23.86, CH2 24.08, CH2 
4, H-a, a-
OH, HCf 
- 4, C-i, C-iii 
        
6 (C-i)d 1.49, m 1.31, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
4, H-a, a-
OH, HCf 
- C-i, C-iii 
        
7 (H-a)e(C-iii)d 3.78, s 3.58, s 
69.8-70.8, 
CH 
69.2-70.2, CH 
4, a-OH, H-
b, HCf 
C-i, 8 - 
        
(7)-OH - 
4.44, d (4.4) 
or 4.47, d 
(4.2) 
- - H-a, HCf - 8, C-i, C-iii 
        
8 1.56, m 1.37 43.51, CH2 44.67, CH2 
H-a, a-OH, 
HCf 
C-i, C-ii, C-
iii 
C-iii 
        
9 (H-a)e(C-iii)d 3.78, s 3.58 
69.8-70.8, 
CH 
69.2-70.2, CH 
4, a-OH, H-
b, HCf 
C-i, 8 - 
        
 (9)-OH - 
4.44, d (4.4) 
or 4.47, d 
(4.2) 
- - H-a, HCf - 8, C-i, C-iii 
        
10 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-a, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
11 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
        
12 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
13 (H-b)e(C-
iii)d 
3.57, s 3.37, s 
69.8-70.8, 
CH 
69.2-70.2, CH 
H-a, H-c, 
HCf 
C-i, C-ii - 
        
(13)-OH - 4.14, d (4.1) - - H-b, HCf - C-i, C-iii 
        
14 (C-i)c 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
 
Table 3. NMR spectral data for nuiapolide (56)  
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Table 3 Continued 
Positiona 
δH (J in Hz) 
in MeOH-d4 
δH (J in Hz) 
in DMSO-d6 
δC in MeOH-
d4, type 
δC in DMSO-
d6, type 
TOCSY 
HSQC-
TOCSYb 
HMBCc 
15 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
        
16 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
17 (H-b)e(C-
iii)d 
3.57, s 3.37, s 
69.8-70.8, 
CH 
69.2-70.2 
H-a, H-c, 
HCf 
C-i, C-ii - 
        
(17)-OH - 4.14, d (4.1) - - H-b, HCf - C-i, C-iii 
        
18 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
19 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
        
20 (C-i)c 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
        
21 (H-b)e(C-
iii)d 
3.57, s 3.37, s 
69.8-70.8, 
CH 
69.2-70.2, CH 
H-a, H-c, 
HCf 
C-i, C-ii - 
        
(21)-OH - 4.14, d (4.1) - - H-b, HCf - C-i, C-ii 
        
22 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
23 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
        
24 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
25 (H-b)e(C-
iii)d 
3.57, s 3.37, s 
69.8-70.8, 
CH 
69.2-70.2, CH 
H-a, H-c, 
HCf 
C-i, C-ii - 
        
(25)-OH - 4.14, d (4.1) - - H-b, HCf - C-i, C-iii 
        
26 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
27 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
        
28 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
29 (H-b)e(C-
iii)d 
3.57, s 3.37, s 
69.8-70.8, 
CH 
69.2-70.2, CH 
H-a, H-c, 
HCf 
C-i, C-ii - 
        
(29)-OH - 4.14, d (4.1) - - H-b, HCf - C-i, C-iii 
        
30 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
31 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
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Table 3 Continued 
Positiona 
δH (J in Hz) 
in MeOH-d4 
δH (J in Hz) 
in DMSO-d6 
δC in MeOH-
d4, type 
δC in DMSO-
d6, type 
TOCSY 
HSQC-
TOCSYb 
HMBCc 
32 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
33 (H-b)e(C-
iii)d 
3.57, s 3.37, s 
69.8-70.8, 
CH 
69.2-70.2, CH 
H-a, H-c, 
HCf 
C-i, C-ii - 
        
(33)-OH - 4.14. d (4.1) - - H-b, HCf - C-i, C-iii 
        
34 (C-i)d 1.48-1.59, m 1.24-1.41, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-ii, C-
iii 
        
35 (C-ii)d 1.31-1.55, m 1.19-1.37, m 
20.8-21.5, 
CH2 
21.4-22.0, 
CH2 
H-b, HCf 
C-i, C-ii, C-
iii 
C-i, C-iii 
        
36 (C-i)d 1.42, m 1.28, m 
36.2-37.4, 
CH2 
37.2-38.1, 
CH2 
H-b, HCf 
37, C-i, C-
ii, C-iii 
C-i, C-ii, C-
iii 
        
37 (H-c)e 3.42, m 3.25, m 67.58, CH 67.25, CH 
H-b, c-OH, 
39 
C-i - 
        
(37)-OH - 4.15, d (5.58) - - 39, H-b, HCf - 
38, C-i, C-
iii 
        
38 1.58, m 1.44, m 37.55, CH2 38.56, CH2 
H-c, c-OH, 
HCf 
37, 39 C-i,  C-iii 
        
39 
5.02, dd (9.7, 
2.5) 
4.94, dd (9.7, 
2.5) 
76.82, CH 76.91, CH 
H-c, c-OH, 
41-43, 44, 
HCf 
38 
1, 37, 38, 
40, 41-43 
        
40 - - 33.91, C 34.60, C - - - 
        
41-43 0.93, s 0.85, s 25.00, CH3 26.27, CH3 2, 39 - 39, 40 
        
44 1.96, s 1.87, s 23.89, CH3 24.91, CH3 39 2, 5 2, 3, 4 
a 1
H NMR and 
13
C NMR in methanol-d4 and DMSO-d6 in the left four columns and 2D 
NMR correlations in the right four columns for each position were shown on the table.
 
b
 HSQC-TOCSY correlations are 
1H → 13C, and correlations at the same position are 
excluded.
 
c
 HMBC correlations are 
1H → 13C. 
d
 Three grouped 
13
C NMR peaks are marked as C-i, C-ii, and C-iii. 
e
 Three 
1
H NMR peaks of protons on hydroxyl carbons are marked as H-a, H-b, and H-c. 
f
 HC is overlapped hydrocarbon peaks at 1.31-1.59 (methanol-d4) and 1.19-1.41 
(DMSO-d6) in 
1
H NMR. 
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Figure 40. Structure of nuiapolide (56) and caylobolides A (57) and B (58) 
 
 
 
SIGNIFICANCE 
 
 A novel bioactive natural product, nuiapolide (56) isolated from the marine 
Cyanobacterium has been shown anti-chemotactic activity against Jurkat cells at 
concentrations as low as 1.3 µM. The compound has been identified as a macrolactone 
containing 40 membered ring structure with 9 almost equally distributed hydroxyl 
groups. The compound also contains isobutyl at the α position of oxygen linkage of the 
ester functional group, and an alkene and methyl substation at the α and β positions of 
carbon linkage respectively. This structure is closely related to the previously described 
class of antitumor natural products, caylobolides, which were also isolated from 
Cyanobacteria Lyngbya majuscule for caylobolide A and Phormidium spp. for 
caylobolide B.
166, 167
 
 Cyanobacteria is a phylum of bacteria which produce energy through 
photosynthesis. Because of gaseous oxygen produced as a byproduct of photosynthesis, 
it is believed that the bacterial metabolism was the primary cause of oxidation of the 
ancient earth. This allowed the planet to be habitable for most current organisms which 
56 
57 
58 
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rely on cellular respiration. Cyanobacteria are found almost everywhere in the terrestrial 
and aquatic habitats, and aquatic Cyanobacteria are known as producers of toxic 
secondary metabolites, cyanotoxins. When they bloom on the surface of lake or ocean, 
the concentrated bacteria produce a variety of toxic natural products, including the 
groups of cyclic peptides, alkaloids, and polyketides.
168, 169
 These and other bioactive 
secondary metabolites are recently recognized as research targets through the 
development of harvesting, cultivation, and isolation techniques of single bacterium.
170-
172
 The novel product evaluated in this project provides an example in the database of 
Cyanobacterial bioactive natural products. 
 The structure of nuiapolide (56) suggests that the backbone of the compound is 
produced by PKSs, and the sequential substitutions of hydroxyl groups in every four 
carbons suggests that the majority of the carbon chain is extended in an iterative PKS 
containing at least KR, DH, and ER domains in addition to fundamental AT, KS, and 
ACP domains. Evaluation of the biosynthesis of the molecule would be one future 
project. It is essential to identify the species of the Cyanobacterium and to obtain the 
biosynthetic gene cluster of nuiapolide (56). Understanding of the biosynthetic pathway 
would lead to the bio-engineered production of its bioactive analogs. The other interest 
of the natural product is to identify the mechanism of action. It shares several features 
with caylobolides, such as simple substitutions around the ester functional group, a long 
cyclic carbon chain, and several hydroxyl substitutions on the chain. Through the 
synthetic and analogous bioactive studies, the pharmacophore of the compounds could 
be determined, and synthetic small molecules which share the pharmacophore may be 
useful for cancer or other disease therapies.  
 
METHODS AND MATERIALS 
 
General Experimental Procedures 
High resolution ESI-MS spectra were measured on an Agilent 6530 QTOF mass 
spectrometer with an Agilent 1200 HPLC system. Unit-resolution ESI-MS spectra were 
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performed on a Thermo Finnigan LCQ Deca XP Max ion trap mass spectrometer using 
ESI ionization interfaced with an Agilent 1100 HPLC, Thermo Finnigan Surveyor 
photodiode array (PDA) detector, and a SEDEX 75 Evaporative light scattering detector 
(ELSD).  Preparative HPLC was performed using an Agilent 1100 binary preparative 
system with an Agilent multi-wavelength UV detector.  An inverted microscope (VWR, 
Radnor, Pennsylvania, USA) was used for evaluation of Jurkat cells.  Photographs of the 
cells were taken with X100 magnification (X10 ocular and X10 objective lens) and a 
camera (Olympus, Shinjuku, Tokyo, Japan) equipped with a modified lens piece, which 
fits over the microscope eyepiece. Cell cycle analysis of Jurkat cells was performed with 
a flow cytometer (FACSCalibur, Becton Dickinson, Franklin Lakes, New Jersey, USA).  
NMR spectra were acquired on a Bruker Avance III 500 MHz spectrometer equipped 
with a 5 mm H-C-N cryoprobe (Bruker Corporation, Billerica, Massachusetts, USA) at 
500 MHz for 
1
H NMR and 125 MHz for 
13
C NMR in methanol-d4 or DMSO-d6. 
 
Reagents and Chemicals 
 Jurkat clone E6-1, its culture medium RPMI 1640, and fetal bovine serum (FBS) 
were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). 
Triton X-100, DNase-free RNase, propidium iodide, and ampules of NMR solvents 
(methanol-d4 and DMSO-d6) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).   
 
Sample Preparation for Assay Analysis (Hawaii Pacific University) 
 The 560 crude extracts were prepared from freeze dried samples of 
microorganisms collected from near-shore environments in the main Hawaiian islands.  
Active sample 13-F10, was prepared from a colonial cyanobacterium (071905-NII-01). 
Specifically, the freeze-dried cyanobacterium sample (105 mg) was extracted in H2O (10 
mL) with sonication.  The water extracted was filtered and loaded on a C-4 solid phase 
extraction (SPE) cartridge (500 mg, 300 Å).  The cartridge was washed with H2O (10 
mL) and the H2O wash was discarded.  The column was then eluted with methanol/water 
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mixtures (33:67, 67:33, and 100:0; 6 mL each).  The combined fractions were dried 
under vacuum (3.9 mg) and added to our extract libraries as 13-F10.  Prior to assay, a 
small portion of the extract was dissolved in methanol/ethyl acetate/t-butyl methyl ether 
(60:30:10) (MET) and transferred to a 96-well plate.  The plates were stored desiccated 
and vacuum packed at -20 °C.  Each 96-well plate of extracts was solubilized in MET 
and evaluated in our chemotaxis transwell assay. 
 
Details on Cyanobacteria Biomass (Hawaii Pacific University) 
 Colonies of the red filamentous cyanobacterium were collected by hand on July 
19, 2005 at a depth of 12-20 m in waters adjacent to Lehua Rock, an islet off the east 
shore of Niihau, Hawaii.  Samples were kept on ice in the field before freezing at -15 °C.  
The frozen samples were then freeze-dried. A dried voucher specimen (071905-NII-01) 
is deposited in the Department of Natural Sciences, Hawaii Pacific University and a 
partial 16S rRNA gene sequence was deposited in the NCBI GenBank under the 
accession number KT852581. 
 
DNA Extraction and Sequencing (Hawaii Pacific University) 
DNA was extracted using a Qiagen DNeasy kit. A small portion of frozen 
biomass was thawed and warmed to 55 °C. Lysis buffer (“ATL” buffer, 180 L) and 
proteinase K solution (600 mAU/mL; 20 L) were added, and the mixture was vortexed, 
then incubated overnight a 55 °C. After warming the mixture to 70 °C, the sample was 
again vortexted, and chaotropic “AL” buffer (200 L) was added, followed by a 10 min 
incubation. The sample was then mixed thoroughly with ethanol (200 L) and pipetted 
into the DNeasy mini-spin column, which was placed in a collection tube and 
centrifuged at 6,000 g for 1 min. The column was washed by centrifuging again at 6,000 
g for 1 min after adding the chaotropic elution buffer “AW1” (500 L) and again with  
wash buffer “AW2” (500 L) and centrifuging again at 20,000 g for 3 min.  Elution 
buffer “AE” (100 L) was added and incubated at room temperature for 1 min, before 
centrifuging at 6,000 g for 1 min.  The DNA eluate was collected and stored at -20 °C. 
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Primers were developed by Nubel and coworkers (1997) to amplify an 
approximate 700 bp region of 16S that allows the specific amplification of 
cyanobacterial 16S genes sequences.
173
 The partial sequencing of 16S was accomplished 
by adding 1 L of thawed isolated DNA to a mixture of H2O (26 L), dNTP (1.0 uL, 
Eppendorf), forward primer (1.0 L, 20 pmol/L, CYA106F: 
CGGACGGGTGAGTAACGCGTGA), and reverse primers (1.0 L, 20 pmol/L, a 1:1 
ratio of CYA781Ra: GACTACTGGGGTATCTAATCCCATT and CYA781Rb: 
GACTACAGGGGTATCTAATCCCTTT) in a PCR tube.  The mixture was heated to 95 
°C for 2 min and the following mixture was added: 14.75 L H2O, 5 uL 10X reaction 
buffer, and 0.25 L Taq polymerase (Eppendorf).  The following cycles were applied:  
10 cycles, 95 °C for 30 sec, 65 °C for 30 sec, the cool -1 °C; 30 cycles, 95 °C for 30 sec, 
55 °C for 30 sec, 68 °C for 1 min.  Finally, the PCR product was held at 68 °C for 7 min 
and then stored at 4 °C.  The PCR product was checked for a single correctly sized 
product by agarose gel electrophoresis, and the band was prepared for sequencing using 
a Qiagen QIAquick spin kit per instructions.  Sequencing was conducted by the by the 
Greenwood Molecular Biology Facility (University of Hawaii) employing the ABI 
Prism BigDye Terminator and Primer Cycle Sequencing Chemistries and an ABI 377XL 
capillary sequencer. 
A tblastx search against the NCBI database with E-value cutoff of ≤ 1.0E-3 
revealed a highly significant hit to Okeania plumata (KC986934.1).
174
 
 
Scaled-Up Extraction of the Active Cyanobacterial Species (Hawaii Pacific 
University) 
For process and storage efficiency, the bulk of our library samples are routinely 
extracted in organic solvents.  Sample 071905-NII-01 (5.6 g dry wt) was extracted 
repeatedly with methanol (65 mL and 2 x 50 mL) followed by dichloromethane (2 x 50 
mL). The methanol extracts were combined and solvent was removed under vacuum to 
yield 1.8 g of extract residue.  The dichloromethane extracts were also combined and 
solvent removed under vacuum to yield 34 mg. Analytical amounts of both extracts were 
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subject to bioassay-linked fractionation in order to identify the active component(s) of 
the organism. 
 
Bioassay-Linked Fractionation of Methanol and Dichloromethane Extracts of the 
Cyanobacterium 071905-NII-01 (Hawaii Pacific University) 
Both extracts (dichloromethane, 1.7 mg, FP1; methanol, 2.0 mg, FP2) were 
fractionated in two runs each by reversed-phase HPLC (Phenomenex Luna C18-2 
column, 5 μm, 4.6 × 250 mm) using a linear gradient of acetonitrile/water (FP1: 50:50 to 
100:0 over 0-15 min, then 100% acetonitrile from 15-26 min; FP2: 20:80 to 100:0 over 
0-15 min, then 100% acetonitrile from 15-26 min; flow rate: 1.0 mL/min; UV detection: 
200-600 nm).  Extract components eluting between 2.0-26.0 min were collected as 60-
sec fractions into a deep 96-well plate.  For each extract, both HPLC runs were collected 
into the same deep-well plate and solvent was removed from the plates under vacuum in 
a centrifugal concentrator at room temperature.  Fractions were reconstituted with MET 
and apportioned into low profile 96-well plates for bioassay, averaging 45 and 60 
g/well for FP1 and FP2, respectively.  Prior to assay, the fractions were reconstituted 
and diluted in MET and tested as average concentrations of 1, 10, and 25 g/mL.  For 
FP1, the activity concentrated in fractions eluting at 4.0-5.0 and 12.0-14.0 min. And for 
FP2, activity concentrated in fractions eluting at 9.0-10.0 and 16.0-17.0 min.  Taken 
together, LCMS of both active regions in both fraction plates indicated the presence of 
the same components in each of the two active regions.  FP1 fractions had only very 
minor impurities.  The major component in the earliest active region for each fraction 
was absent from adjacent inactive fractions and showed a molecular weight of 788.6 
(ESI-positive mode m/z 789.6, MH
+
; ESI-negative mode m/z 787.6 [M-H]
-
).  The second 
active region in FP1 showed of a single low-yielding compound that was absent from 
adjacent inactive fractions.  The major component had a molecular weight of 982.7 (ESI-
positive mode m/z 983.5, MH
+
, m/z 1005.5, MNa
+
;  ESI-negative mode m/z 981.9 [M-
H]
-
). 
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Isolation of Nuiapolide (56) (Hawaii Pacific University) 
 The major component from the first active fraction in FP1 and FP2 was isolated 
from the methanol extract, guided by LCMS (ESI-positive mode m/z 789.6, MH+; ion 
trap analyzer).  The methanol extract (1,020 mg) was dissolved in methanol and cleaned 
up for HPLC by eluting in 7 batches from an SPE column (C18 silica, 1 g, EM 110167-
4) with methanol (17 mL each).  The eluate was concentrated under vacuum to dryness 
(996 mg), reconstituted in methanol/water 90:10 (14 mL) and chromatographed in 7 
portions by preparative reversed phase HPLC (Phenomenex Luna C18-2 column, 5 μm, 
22 × 250 mm; flow rate: 18 mL/min; methanol/water linear gradient 70:30 to 100:0 from 
0-15 min, then 100% methanol from 15-30 min).  Peaks were collected based on 
absorbance at 210 nm and analyzed by LCMS.   Compound 1, nuiapolide, eluted at 8.6 
min (50.7 mg, 0.89% yield, dry wt).  The purity of nuiapolide (1) (>95%) was 
determined by LCMS-ELSD analysis (Phenomenex Luna C18-2 column, 5 μm, 2 × 250 
mm; flow rate: 0.20 mL/min;  acetonitrile/water gradient 50:50 to 100:0 over 0-10 min, 
then 100% acetonitrile 10-20 min; ELSD 50 °C; PDA 200-600 nm). 
 
Structural Analysis of Nuiapolide (56) 
 Nuiapolide (56): chartreuse amorphous solid; [α]25D -12 (CH3OH, c 0.341);  
1
H 
and 
13
C NMR data (methanol-d4 and DMSO-d6), see Table 3 and Figure 41-Figure 55; 
HR-TOF-ESIMS, m/z [M+H]
+
  789.6076 (calcd for C44H85O11, 789.6092, ∆ -2.2 ppm), 
[M+Na]
+
 811.5895 (calcd for C44H84O11Na, 811.5911, ∆ -2.0 ppm). NMR spectra were 
recorded on a Bruker Avance III.  The purified sample (500 µg) was dissolved in 500 µL 
of methanol-d4 or DMSO-d6, which was transferred into a 3 mm NMR sample tube 
(Wilmad LabGlass, Vinelandk, NJ, USA). 
1
H NMR, 
13
C NMR, 
13
C NMR DEPT, COSY, 
TOCSY, HSQC, HSQC-TOCSY, and DMSO-d6  were acquired in methanol-d4 at 298 K 
(Figure 41-Figure 49 for spectra; Table 3 for assignments), and 
1
H NMR, 
13
C NMR, 
COSY, TOCSY, and HMBC were recorded in DMSO-d6 at 315 K (Figure 50-Figure 
55).  
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Chemotaxis and Cytotoxicity Assay against Jurkat Cells, Human Cell Line of T 
Lymphocyte 
 Chemotaxis and cytotoxicity assays of crude or purified extracts against Jurkat 
cells were performed as described in Chapter III assessing the activities of aziA2 
disruption mutant and dimethyl furan-2,4-dicarboxylate (55) except for the solvent, 
which was MET solution. 
 
Cell Cycle Analysis by Flow Cytometry 
 The effect of nuiapolide (56) on the cell cycle was assessed by flow cytometry. 
Jurkat cells were harvested by centrifugation and counted following the same procedures 
as detailed in previous sections. Cells were added to RPMI cell culture medium in 24-
well plates to give a final concentration of 400,000 cells/mL, 500 L total volume. 
Nuiapolide (56) was added (5.0 µg/mL) and the cells were incubated at 37 
o
C in 5% CO2 
for 2, 4, or 6 h. The resulting cells were prepared for flow cytometry analysis based on 
published procedures.
175
 Cells were transferred into a 15-mL falcon tube and harvested 
by centrifugation at 1,000 rpm for 10 min. Cells were subsequently washed with 5 mL of 
PBS and pelleted at 1,000 rpm for 6 min. The supernatant was removed and the cells 
were resuspended in 0.5 mL of PBS. The cell suspension was transferred into 4.5 mL of 
ice cold ethanol and stored on ice (or -20 
o
C) for more than 2 h.  The ethanol fixed cells 
were collected by centrifugation at 1,000 rpm for 5 min. The cell pellet was resuspended 
in 5 mL of PBS, incubated for 1 min and centrifuged again at 1,000 rpm for 5 min. The 
cell pellet was finally resuspended in 1 mL of freshly prepared staining solution (PBS, 
0.1% of Triton X-100, and 0.2 mg/mL of DNase-free RNase, and 0.02 mg/mL of 
propidium iodide), and incubated at room temperature for 30 min before analyzing the 
samples by flow cytometry using a 488 nm argon laser. 
 
Spectral Data of Nuiapolide (56) 
Nuaipolide (56): 
1
H NMR (methanol-d4, 500 MHz): δH 0.93 (9H, s, CH341, CH342, and 
CH343), 1.31-1.55 (14H, overlapped m, CH211, CH215, CH219, CH223, CH227, CH231, 
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and CH235), 1.48-1.59 (26H, overlapped m, CH210, CH212, CH214, CH216, CH218, 
CH220, CH222, CH224, CH226, CH228, CH230, CH232, and CH234),  1.42 (2H, m, 
CH236), 1.49 (2H, m, CH26), 1.56 (2H, m, CH28), 1.58 (2H, m, CH238), 1.60 (2H, m, 
CH25), 1.96 (3H, s, CH344), 2.58 (1H, m, H4’), 2.83 (1H, m, H4’’), 3.42 (1H, m, H37), 
3.57 (6H, s, H13, H17, H21, H25, H29, and H33), 3.78 (2H, s, H7 and H9), 5.02 (1H, 
dd, J = 9.7, J = 2.5 Hz, H39) 5.74 (1H, s, H2). 
1
H NMR (dimethyl sulfoxide-d6, 500 
MHz): δH 0.85 (9H, s, CH341, CH342, and CH343), 1.19-1.37 (14H, overlapped m, 
CH211, CH215, CH219, CH223, CH227, CH231, and CH235), 1.24-1.41 (26H, overlapped 
m, CH210, CH212, CH214, CH216, CH218, CH220, CH222, CH224, CH226, CH228, 
CH230, CH232, and CH234), 1.28 (2H, m, CH236), 1.31 (2H, m, CH26), 1.37 (2H, m, 
CH28), 1.44 (2H, m, CH238), 1.49 (2H, m, CH25), 1.87 (3H, s, CH344), 2.59 (2H, m, 
CH24), 3.25 (1H, m, H37), 3.37 (6H, s, H13, H17, H21, H25, H29, and H33), 3.58 (2H, 
s, H7 and H9), 4.14 (6H, d, J = 4.1 Hz, OH13, OH17, OH21, OH25, OH29, and OH33), 
4.15 (1H, d, J = 5.6 Hz, OH37), 4.44 (1H, d, J = 4.4 Hz, OH7 or OH9), 4.47 (1H, d, J = 
4.2 Hz, OH7 or OH9), 4.94 (1H, dd, J = 9.7, J = 2.5 Hz, H39), 5.67 (1H, s, H2). 
13
C 
NMR (methanol-d4, 500 MHz): δC 20.8-21.5 (C11, C15, C19, C23, C27, C31, and C35), 
23.86 (C5), 23.89 (C44), 25.00 (C41, C42, and C43), 32.69 (C4), 33.91 (C40), 36.2-37.4 
(C6, C10, C12, C14, C16, C18, C20, C22, C24, C26, C28, C30, C32, C34, and C36), 
37.55 (C38), 43.51 (C8), 67.58 (C37), 69.8-70.8 (C7, C9, C13, C17, C21, C25, C29, and 
C33), 76.82 (C39), 115.73 (C2), 161.20 (C3), 166.90 (C1). 
13
C NMR (dimethyl 
sulfoxide-d6, 500 MHz): δC 21.4-22.0 (C11, C15, C19, C23, C27, C31, and C35), 24.08 
(C5), 24.91 (C44), 26.27 (C41, C42, and C43), 33.11 (C4), 34.60 (C40), 37.2-38.1 (C6, 
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C10, C12, C14, C16, C18, C20, C22, C24, C26, C28, C30, C32, C34, and C36), 38.56 
(C38), 44.67 (C8), 67.25 (C37), 69.2-70.2 (C7, C9, C13, C17, C21, C25, C29, and C33), 
76.91 (C39), 116.69 (C2), 160.04 (C3), 166.04 (C1). HR-TOF-ESIMS, m/z [M+H]
+
  
789.6076 (calcd for C44H85O11, 789.6092,  -2.2 ppm), [M+Na]
+
 811.5895 (calcd for 
C44H84O11Na, 811.5911,  -2.0 ppm). 
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CHAPTER V 
 
CONCLUSION 
 
 Natural products have been used as therapeutic agents since the beginning of 
human history and still play an important role in drug discovery. Use of natural products 
for therapeutic purposes is thought to be one of the most primitive behaviors of human 
beings because it is seen even in animals such as mammals and birds. Humans could 
investigate how natural products affected their health and inherited the knowledge over 
generations. Natural product drugs have become purer and purer through the 
technological and scientific advancement. From crude drugs found within an organisms’ 
extract, single natural product drugs were established by the discovery of penicillin in 
1928. Since then, scientists started exploring novel natural products from plants or 
microorganisms, which led to a great expansion of the bioactive compound database. 
The database keeps enlarging not only with new natural products but also with 
chemically or biologically modified non-natural natural products. These modification 
techniques are very important in current drug discovery, however both techniques have 
limitations. The chemical modification tends to yield reasonable amount of analogous 
products, but it often cannot replicate the complexities of natural products. The 
biological modification can replicate these complexities, but it does not produce a high 
amount of engineered products. Understanding of biosynthetic pathway and enzyme 
functions is essential for the efficient utilization of combinatorial biosynthesis. 
 Azinomycins, antitumor agents produced by the soil bacterium Streptomyces 
sahachiroi, are suitable targets to further our enzymatic understanding because they are 
biosynthesized by a combination of large enzyme families: NRPSs, PKSs, and alkaloid 
producing enzymes. Evaluation of their functions and interactions would greatly benefit 
bioengineering utilizing these common enzymatic families together. Even the seemingly 
simplest part of their biosynthesis, production of the naphthoate moiety by the PKS 
(AziB), was shown to be more complex than the well studied biosynthesis of aromatic 
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polyketides; AziB required interaction with a TE domain (AziG) to yield the fully 
elongated product. This implies the database which is used for bioinformatic studies 
would not be large enough to accurately predict enzymatic functions and would lack the 
crucial information for protein-protein or domain-domain interactions. Our enzymatic 
knowledge, in other words, needs to be improved more for effective engineered 
biosynthesis of non-natural natural products.  
 Assembling the naphthoic acid into the azinomycin structure by NRPSs is 
another mystery whose mechanism could not be drawn only by bioinformatic studies 
due to an extra domain, AziA2. Transferring the naphthoic acid from AziA1 to AziA2 
without any structural modifications seems to be energetically inefficient. However, 
disruption of aziA2 in the genomic DNA of S. sahachiroi revealed that this domain was 
essential for the azinomycin production. The same phenomenon can be observed in other 
PKS or NRPS biosynthetic pathways containing apparently unnecessary domains. This 
indicates again that our enzymatic knowledge has a lot room to improve. The aziA2 
disruption mutant also displayed an example of bacterial adaptation. Overproduction of 
dimethyl furan-2,4-dicarboxylate in the disruption mutant suggested that a gene cluster 
which is silenced in the wild type S. sahachiroi was activated by a change of the internal 
environment, in this case the absence of azinomycin production. This suggests that yield 
of a natural product could be increased by disruption of other natural products’ 
biosynthesis in an organism.  
 Most natural products isolated to date are found in terrestrial organisms because 
of their ease to harvest and culture. Oceans cover 70 % of earth’s surface and have been 
thought to be a large source of novel natural products. Recent technological and 
scientific advancement has allowed researchers to explore marine natural products, 
which have successfully provided potent therapeutic agents. The novel macrolactone 
bioactive natural product nuiapolide was discovered and isolated from a marine 
cyanobacterium. The proposed anti-metastatic activity could provide a solution or hint 
for therapies targeting cancer metastasis which is one of the critical barriers in cancer 
treatment. The molecular structure of nuiapolide resembles a previously described class 
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of anti-tumor natural products, the caylobolides, which were also isolated from 
cyanobacteria. Further evaluation of these compounds for their biosynthetic pathway 
would be beneficial for bio-engineering purposes, and the large but relatively simple 
structure would ease the synthetic study to identify the pharmacophore and to produce 
bioactive analogs. 
 The following topics were discussed in this dissertation: the novel PKS-TE 
domain interaction involved in polyketide biosynthesis, bioactivity assays of dimethyl 
furan-2,4-dicarboxylate which was overproduced in S. sahachiroi aziA2 disruption 
mutant, and discovery of the novel bioactive marine natural product nuiapolide. Each 
project provided different outcomes; the first one provided enzymatic perspective in the 
polyketide production, the second displayed bacterial adaptation, and the last added a 
compound into the marine natural product database. These achievements would present 
novel scientific insights into natural product chemistry.  
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APPENDIX 
Appendix Figure 56. BLAST search of AziB 
AziB peptide sequence was searched for homology by BLAST. It shows the distinct five 
domains including KS,
176
 AT,
177
 DH,
112, 178, 179
 KR,
180
 and ACP
181
 domains.
Appendix Figure 57. Multiple alignment of AziB and its homologous enzymes (0-
400 aa) 
ChlB1 (Identity: 45%, NCBI accession number: AAZ77673.1),
113
 NcsB (52%,
AAM77986.1),
114
 and PokM1 (46%, ACN64831.1).
115
FIGURES AND TABLES
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Appendix Figure 58. Preparation of pure AziA6 
(a): Cloned expression vector of AziA6. (b): Bradford assay for each fraction in 
Sephadex column filtration. (c): SDS-PAGE analysis of Sephadex column fractions. 
Appendix Figure 59. BLAST search of AziG 
148 
Appendix Table 4. Characterized homologous enzymes of AziG 
Accession no. Organism Protein E-value Identity/similarity 
(%) 
AziG (comparison with TEs characterized by crystallography and kinetics) 
1Q4S_A Arthrobacter sp. 
SU 
PaaI TE 
(hotdog) 
4e-14 37/56 
4K49_C E. coli K-12 PaaI TE 
(hotdog) 
4e-12 33/45 
1J1Y_A Thermus 
Thermophilus Hb8 
PaaI TE 
(hotdog) 
1e-09 35/51 
Appendix Figure 60. Multiple alignment of AziG and its characterized homologous 
enzymes which share the conserved active site 
4-HB-CoA TE (Identity: 37%, Similarity: 56%, PDB accession number: 1Q4S_A).
120
Ydii (33%, 45%, 4K49_C),
121
 PaaI (35%, 51%, 1J1Y_A),
122
149 
Appendix Figure 61. AziG tetramer and monomer 
The monomer adopts the characteristic hotdog fold with the β-sheet of each monomer 
facing the core and the main α-helices facing outward. 
150 
 
 
 
Appendix Table 5. NMR spectral data for 5-methyl-1-naphthoic acid (49) (500 
MHz, CD3OD). 
5-methyl-1-naphthoic acid (49) 
Position δC, type δH (J in Hz) HMBC
a
1 125.8, C 
2 130.4, CH 8.120, d (7.8) 4, 10, 11 
3 125.5, CH 7.574, t (7.8) 1, 5 
4 130.0, CH 8.268, d (8.4) 2, 10 
5 134.3, C 
6 135.9, C 
7 128.0, CH 7.388, d (7.1) 5, 9 
8 128.1, CH 7.450, t (9.1) 6, 10 
9 125.0, CH 8.649, d (9.1) 5, 8 
10 132.6, C 
11 171.5, C 
12 20.0, CH3 2.704 5, 6, 7 
a
HMBC correlations are 
1H→13C
Appendix Figure 62. Expression plasmid of AziG (and its mutants) and SDS-PAGE 
analysis of overexpression and purification 
(a): aziG was cloned into pET-24a and was mutated by site-directed mutagenesis. (b): SDS-
PAGE analysis after overexpression and purification of AziG WT and mutants (M: protein 
marker, 1: WT, 2: H44A, 3: H48A, 4: E57A, 5: S58A, 6: S61A).  
(a) (b) 
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Appendix Figure 63. Numbering of 5-methyl-1-naphthoic acid (49) and HMBC 
correlations 
Appendix Figure 64. LC-MS analysis with the standard 
The crude standard gave multiple peaks in the LC profile (pink line), but when it was co-
injected with the AziB-AziG product (red line), only one peak appeared (green arrow) 
which matches the mass of the AziB-AziG product. 
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Appendix Figure 76. Individual kinetic parameters including R
2
 values and error
bars of standard deviations 
164 
Appendix Scheme 5. AziG kinetic experiment utilizing Ellman’s reagent 
Appendix Figure 77. Determination of molar absorptivity of Ellman’s reagent in 
the reaction buffer 
y = 8860x 
R² = 0.982 
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Appendix Figure 78. Gel filtration of native AziG 
(a): Elution profile of 1 bovine serum albumin, 2 ovalbumin, 3 carbonic anhydrase, and 
4 cytochrome C, (b): native AziG, (c): overlay of AziG with standards. 
(a) 
(b) 
(c) 
1 
1 2 
2 3 
3 
4 
4 
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Proteins 
Molecular 
Mass (kDa) 
Elution 
Volume (mL) 
BSA 67 55.6 
ovalbumin 45 61.0 
Carbonic 
anhydrase 29 69.2 
Cytochrome C 13 81.6 
AziG 62 55.6 
Appendix Figure 79. Gel filtration analysis of AziG: calibration curves and 
tabulated data 
y = -0.475x + 85.1 
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Appendix Table 6. AziG data collection and refinement statistics 
AziG AziG/3-hydroxy-2-
NPA
beamline CHESS F1 NE-CAT ID-E 
resolution (Å) 2.15 2.4 
wavelength (Å) 0.9183 0.97919 
space group I4122 I4122 
a (Å) 68.5 68.2 
c (Å) 139.6 139.7 
Matthews coefficient 2.73 2.71 
% solvent 54.9 54.6 
mol/asu 1 1 
Measured reflections 62888 36636 
Unique reflections 9373 6783 
Average I/σ 37.3(5.8) 22.2(3.6) 
Redundancy 6.7(5.7) 5.4(5.5) 
Completeness (%) 99.5(100) 99.6(100) 
Rmerge (%)
b
9.1(38.6) 9.4(35.6) 
No. of protein atoms 920 927 
No. of ligand atoms 0 14 
No. of water atoms 34 28 
Reflections in working 
set
8883 6448 
Reflections in test set 446 323 
R-factor (%) 22.2 20.2 
Rfree (%) 26.6 25.0 
rms deviation from 
ideals
bonds (Å) 0.007 0.008 
angles (deg) 1.17 1.101 
average B factor for 
protein (Å
3
)
45.2 26.4 
Ramachandram plot 
m st favored (%) 95.1 96.7 
allowed (%) 4.9 3.3 
disallowed (%) 0 0 
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Appendix Figure 80. Cytotoxicity and chemotaxis assay against Jurkat cells 
Microscopic images of the assays. Cytotoxicity assay: Cy C1: control without FBS in 
the culture medium, Cy C2: control without any samples, Cy C3: control with FTY720 
(1.0 µg/mL), Cy C4: control with FTY720 (0.75 µg/mL), Cy C7: control with 1 µL of 
stock solution (methanol/ethyl acetate/t-butyl methyl ether = 60/30/10), Cy ∆A2: aziA2 
disruption mutant extract, Cy WT: wild type extract, Cy DL: 1 µg/mL of dimethyl furan-
2,4-dicarboxylate, Cy DM: 10 µg/mL, Cy DH: 25 µg/mL. Chemotaxis assay: Ch C1: 
control without FBS in the bottom well, Ch C2: control without any samples, Ch C3: 
control with FTY720 (1.0 µg/mL), Ch C4: control with FTY720 (0.75 µg/mL), Ch C7: 
control with 1 µL of stock solution, Ch ∆A2: aziA2 disruption mutant extract, Ch WT: 
wild type extract, Ch DL: 1 µg/mL of dimethyl furan-2,4-dicarboxylate, Ch DM: 10 
µg/mL, Ch DH: 25 µg/mL. 
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Appendix Figure 81. Chemotaxis assay of CL013-F10 at lower doses 
Microscopic images of the bottom well of Boyden chambers after 24 h incubation; (a): 1 
µg/mL, (b): 10 µg/mL, and (c): 25 µg/mL of CL013-F10. 
Appendix Figure 82. PDA map of active fractions in FR022 
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Appendix Figure 83. LCMS analysis of FR022 
The molecular weight was determined as 788.6±0.2 Da based on monomer and dimer 
adducts. 
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Appendix Figure 84. PDA map of active fractions in FR023 
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Appendix Figure 85. LCMS analysis of NP988 
The molecular weight was determined as 982.7±0.2 Da based on monomer adducts. 
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Appendix Figure 86. Purified nuiapolide (56) and NP982 
(a): Nuiapolide (56, NP788) was purified sufficient amount. (b): NP982 was purified 
insufficient amount. 
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Appendix Figure 87. Chemotaxis assay for purified active fractions 
The fractions were assessed for ability of inhibiting chemotaxis of Jurkat cells at the 
concentrations of 1, 10, and 25 µg/mL. The other sample KK1-62-10 was the fraction 
between active fractions, indicating no activity of the fraction. 
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Appendix Figure 88. Cell cycle analysis of nuiapolide (56) treated Jurkat cells 
Left: light-scattering properties of cells/nuclei, Middle: Histogram with modeled cell 
cycle components, and Right: appearance of cells 
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Appendix Figure 89. Number of carbons in 
13
C NMR grouped regions 
Top right: 21.4-22.0 ppm in DMSO-d6. Top left: 69.2-70.2 ppm in DMSO-d6. Bottom 
right: 36.2-37.4 ppm in methanol-d4. Bottom left: 37.2-38.1 ppm in DMSO-d6. 
